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Abstract 
 
Cystic fibrosis (CF) is a life-threatening autosomal genetic disease, which affects 
approximately 48,204 individuals in Europe and 29,887 in the USA. This condition is 
caused by mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR). In CF, the mutated CFTR, in the case of F508, causes accumulation of 
misfolded proteins leading to endoplasmic reticulum (ER) stress, with activation of the 
IRE1-XBP1 pathway. This pathway is essential in the regulation of a subset of genes 
controlling proinflammatory and metabolic responses in immune cells; nevertheless, 
the metabolic rates of immune cells and the role of this pathway in CF remain elusive. 
In this study, it was shown that innate immune cells from patients with CF show 
significantly higher levels of ER stress, particularly in the IRE1-XBP1 signalling 
pathway. Interestingly, ER stress was only present in neutrophils, monocytes and 
macrophages from patients with CF. Overactivation of the IRE1-XBP1 signalling 
pathway rewires M1 macrophages from patients with CF, and increases 
macrophages’ metabolic rates, with high glycolytic rates and mitochondrial function. 
The increased activity of the IRE1-XBP1 signalling pathway and the increased 
metabolic rates were associated with excessive production of TNF and IL-6. Specific 
inhibition of the RNase domain of the IRE1 arm decreased the excessive glycolytic 
rates, mitochondrial function and production of inflammatory cytokines. Furthermore, 
Orkambi, Symkevi and Ivacaftor had an essential impact in changing the metabolic 
profile of cells with CF mutations. This study shows how innate immune cells from CF 
patients are affected by ER stress, in particular, M1 macrophages. Moreover, the 
IRE1a-XBP1 signalling pathway is essential for the increased metabolic rates seen in 
 vii
M1 macrophages with CF mutations. Modulation of ER stress might be an exciting 
option to recover the metabolic fitness of cells with CF mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii
Table of Contents 
 
 
Acknowledgements ................................................................................................. iv 
Abstract .................................................................................................................... vi 
Table of Contents .................................................................................................. viii 
Abbreviations ......................................................................................................... xii 
Lists of figures ...................................................................................................... xiv 
Lists of tables ......................................................................................................... xv 
Chapter 1 – Introduction .......................................................................................... 1 
1.1 Cystic Fibrosis ............................................................................................ 1 
1.1.1 The history and pathophysiology of cystic fibrosis .................................. 1 
1.1.2 CF Mutations .......................................................................................... 6 
1.1.3 Understanding the current treatments in CF ........................................... 8 
1.2 Inflammation in CF .................................................................................... 14 
1.2.1 Inflammation in human bronchial epithelial cells ................................... 14 
1.2.2 Animal models of CF and inflammation ................................................ 15 
1.2.3 Monocytes, macrophages and neutrophils in CF .................................. 19 
1.3 ER Stress and the Unfolded Protein Response ...................................... 23 
1.3.1 The UPR signalling pathways ............................................................... 23 
1.3.2 Inflammation and the UPR .................................................................... 26 
1.3.3 CF and the UPR ................................................................................... 29 
1.4 Cellular Metabolism .................................................................................. 32 
1.4.1 Glycolysis and the Krebs cycle ............................................................. 32 
1.4.2 Immunometabolism: macrophage metabolism ..................................... 38 
1.5 Hypotheses ................................................................................................ 42 
1.5.1 List of Hypotheses ................................................................................ 42 
1.5.2 Aims and Objectives ............................................................................. 42 
Chapter 2 – Methods .............................................................................................. 44 
2.1 Cellular culture .......................................................................................... 44 
 ix
2.1.1 Cell Lines .............................................................................................. 44 
2.1.2 Isolation and processing of primary immune cells ................................ 45 
2.1.3 Culture of primary immune cells ........................................................... 47 
2.1.4 Macrophage culture and polarisation .................................................... 47 
2.2 RNA Isolation and detection .................................................................... 48 
2.2.1 RNA isolation and cDNA conversion .................................................... 48 
2.2.2 Real-time PCR (qPCR) ......................................................................... 48 
2.2.3 Reverse transcription PCR (RT-PCR) .................................................. 50 
2.3 Cytokine expression ................................................................................. 51 
2.4 Western blots ............................................................................................ 52 
2.5 Flow cytometry .......................................................................................... 52 
2.6 Immunofluorescence microscopy ........................................................... 54 
2.7 Metabolic experiments ............................................................................. 55 
2.7.1 Cellular ROS detection ......................................................................... 55 
2.7.2 Glycolytic and mitochondrial assays (Extracellular Flux Analyzer) ....... 55 
2.8 Statistical analysis .................................................................................... 57 
2.9 Table of resources .................................................................................... 58 
Chapter 3 – The UPR in Cystic Fibrosis ............................................................... 61 
3.1 Introduction ............................................................................................... 61 
3.2 Methods ..................................................................................................... 62 
3.2.1 RNA isolation and detection ................................................................. 62 
3.2.2 Western blotting .................................................................................... 62 
3.2.3 Flow cytometry ..................................................................................... 62 
3.2.4 Cellular stimulations ............................................................................. 63 
3.3 Results ....................................................................................................... 64 
3.3.1 UPR activation in CF HBEC lines ......................................................... 64 
3.3.2 UPR activation in PBMCs from patients with CF .................................. 74 
3.3.3 No difference in UPR activation in lymphocytes ................................... 76 
3.3.4 BiP, IRE1, ATF4 and CHOP upregulation in neutrophils .................... 78 
3.3.5 IRE1, PERK, ERdj4, ATF4, CHOP and GADD34 upregulation in 
monocytes ............................................................................................ 80 
3.3.6 The IRE1-XBP1 pathway is overactive in CF M1 macrophages......... 83 
 x
3.3.7 XBP1s is not induced in CF M2 macrophages ..................................... 89 
3.4 Discussion ................................................................................................. 90 
Chapter 4 – Inflammation and the UPR in Cystic Fibrosis ................................. 94 
4.1 Introduction ............................................................................................... 94 
4.2 Methods ..................................................................................................... 95 
4.2.1 RNA isolation and detection ................................................................. 95 
4.2.2 Flow cytometry ..................................................................................... 95 
4.2.3 Cytokine expression ............................................................................. 96 
4.2.4 Cellular stimulations ............................................................................. 96 
4.3 Results ....................................................................................................... 97 
4.3.1 Upregulation of IL-6 in CF HBECs ........................................................ 97 
4.3.2 Expression of TNF and IL-6 in lymphocytes and neutrophils ................ 99 
4.3.3 Upregulation of TNF in CF monocytes................................................ 102 
4.3.4 Deficient polarisation of M2 Macrophages in patients with CF ........... 105 
4.3.5 TNF and IL-6 are overexpressed in M1 Macrophages from CF patients .. 
  ........................................................................................................... 107 
4.3.6 IRE1 inhibition reduces TNF and IL-6 in CF M1 Macrophages ........ 111 
4.4 Discussion ............................................................................................... 113 
Chapter 5 – Metabolism in Cells with CF Mutations and the Effects of IRE1 
Inhibition ............................................................................................................... 115 
5.1 Introduction ............................................................................................. 115 
5.2 Methods ................................................................................................... 116 
5.2.1 Cellular ROS detection in HBECs and M1 macrophages ................... 116 
5.2.2 Mitochondrial ROS (mitoSOX) detection ............................................ 117 
5.2.3 Glycolytic and mitochondrial assays ................................................... 117 
5.3 Results ..................................................................................................... 119 
5.3.1 Increased ROS and mitochondrial ROS in CF HBECs ....................... 119 
5.3.2 Increased ROS in CF M1 macrophages ............................................. 121 
5.3.3 Heightened glycolytic rate and mitochondrial flux in CF monocytes ... 122 
5.3.4 Heightened mitochondrial flux and glycolytic rate in CF M1 
macrophages ...................................................................................... 125 
5.3.5 IRE1 inhibition recovers the heightened glycolytic rate and 
mitochondrial flux ................................................................................ 128 
 xi
5.3.6 Ivacaftor reduces OCR levels in CF macrophages with class III 
mutations ............................................................................................ 131 
5.3.7 Orkambi selectively reduces OCR levels in CF macrophages 
(F508/F508) ................................................................................... 136 
5.3.8 Ivacaftor and Symkevi alter the metabolic profile of HBECs ............... 139 
5.4 Discussion ............................................................................................... 145 
Chapter 6 – Discussion ........................................................................................ 148 
6.1 The UPR exacerbates inflammation in cystic fibrosis ......................... 148 
6.2 The UPR and the regulation of macrophage metabolism. ................... 151 
6.3 Abnormal metabolic and inflammatory profiles in CF HBECs ............ 155 
6.4 CF as an autoinflammatory condition ................................................... 156 
6.5 Conclusion ............................................................................................... 158 
6.6 Study limitations ..................................................................................... 160 
6.7 Future Directions .................................................................................... 161 
Appendix ............................................................................................................... 162 
References ............................................................................................................ 165 
 
 
 
 
 
 
 
 
 
 
 
 xii
Abbreviations 
 
2-DG  2-Deoxy-d-glucose 
ASL  Airway surface liquid 
ATF4  Activating transcription factor 4 
ATF6  Activating transcription factor 6 
ATP  Adenosine triphosphate 
B. cepacia  Burkholderia cenocepacia 
BIP  Binding immunoglobulin protein 
BSA  Bovine serum albumin 
CF  Cystic fibrosis 
CFTR  Cystic fibrosis transmembrane conductor regulator 
CHOP  C/EBP homologous protein 
Cl-  Chloride ion 
COPD  Chronic obstructive pulmonary disorders 
DAMP  Danger-associated molecular patterns  
ECAR  Extracellular acidification rate 
eIF2  Eukaryotic initiation factor 2 
ENaC  Epithelial sodium channel 
ER  Endoplasmic reticulum 
ETC  Electron transport chain 
FEV  Forced Expiratory Volume 
FBS  Foetal Bovine Serum 
GADD34 Growth arrest and DNA damage-inducible protein 
GLUT1 glucose transporter 1 
GSH  Glutathione 
HBEC  Human bronchial epithelial cell 
HCO3-  Bicarbonate 
HS  Hypertonic saline 
Hsp  Heat shock protein 
IL  Interleukin 
IRE1  Inositol requiring enzyme 1
LPS  Lipopolysaccharide 
 xiii
mROS Mitochondrial ROS 
NAC  N-acetylcysteine 
NAD+/NADH  Nicotinamide adenine dinucleotide 
NE  Neutrophil extracellular trap 
NF-B  Nuclear factor-kappaB 
NLRP3     NOD-, LRR- and pyrin domain-containing protein 3 
NO  Nitric oxide 
Nrf2  Nuclear factor erythroid 2-related factor 2 
OCR  Oxygen consumption rate 
OxPhos  Oxidative Phosphorylation 
P/S  Penicillin and streptomycin 
PAMP  Pathogen-associated molecular patterns  
PBMC  Peripheral blood mononuclear cells 
PE  Phycoerythrin 
PerCP Peridinin Chlorophyll Protein Complex 
PERK  Double-stranded RNA-activated protein kinase (PKR)-like ER kinase 
PKA  Protein kinase A 
RIDD  Regulated IRE1-dependent decay 
RIPA  Radioimmunoprecipitation assay buffer 
ROS  Reactive oxygen species 
RPMI  Roswell Park Memorial Institute 
S. aureus Staphylococcus aureus 
TLR  Toll-like receptor 
Tg  Thapsigargin 
Tn  Tunicamycin 
TNF  Tumour necrosis factor 
UPR   Unfolded protein response 
XBP1  X box-binding protein 1 
XBP1s X box-binding protein 1 spliced 
  
 


 xiv
Lists of figures 
Figure 1 – History and median predicted survival age for patients with CF ................ 2 
Figure 2 – Cellular pathophysiology of CF HBECs ..................................................... 4 
Figure 3 – Organs affected in CF and common manifestations ................................. 5 
Figure 4 – Prevalence of respiratory pathogens, by age, in respiratory cultures of 
patients with CF ....................................................................................................... 10 
Figure 5 – The UPR signalling pathway ................................................................... 26 
Figure 6 – Glycolysis and the Krebs cycle ................................................................ 33 
Figure 7 – Glycolytic pathway .................................................................................. 34 
Figure 8 – The Krebs cycle ...................................................................................... 36 
Figure 9 – Electron transport chain .......................................................................... 37 
Figure 10 – The Krebs cycle in M1 and M2 macrophages ....................................... 41 
Figure 11 – UPR induction time course. ................................................................... 65 
Figure 12 – UPR activation in CF HBECs ................................................................ 66 
Figure 13 – Activation the BIP, IRE1, ATF6 and PERK. ........................................ 69 
Figure 14 – Activation the XBP1s, XBP1u, eIF2CHOP and GADD34. ................. 72 
Figure 15 – IRE1, pIRE1, ATF6 and PERK protein expression in HBECs ........... 73 
Figure 16 – UPR activation in primary PBMCs from patients with CF ...................... 74 
Figure 17 – ER stress in PBMC stimulated with Tn and Tg ...................................... 75 
Figure 18 – UPR gene expression in lymphocytes from patients with CF ................ 76 
Figure 19 – ER stress in lymphocytes stimulated with Tn and Tg ............................ 77 
Figure 20 – UPR gene expression in neutrophils from patients with CF .................. 78 
Figure 21 – ER stress in neutrophils stimulated with Tn and Tg .............................. 79 
Figure 22 – UPR gene expression in monocytes from patients with CF................... 81 
Figure 23 – ER stress in monocytes stimulated with Tn and Tg ............................... 82 
Figure 24 – Differentiation process of M1/M2 macrophages .................................... 85 
Figure 25 – UPR gene expression in M1 macrophages from patients with CF ........ 86 
Figure 26 – ER stress in M1 macrophages stimulated with Tn and Tg .................... 87 
Figure 27 – XBP1s in M1 macrophages from CF patients ....................................... 88 
Figure 28 – XBP1s is absent in M2 macrophages from CF patients ........................ 89 
Figure 29 – IL-6 expression in HBECs with CF mutations ........................................ 98 
Figure 30 – IRE1 inhibition reduces IL-6 in HBECs. .............................................. 98 
Figure 31 – TNF and IL-6 expression in lymphocytes. ........................................... 100 
Figure 32 – TNF and IL-6 expression in neutrophils............................................... 101 
Figure 33 – TNF and IL-6 expression in monocytes. .............................................. 103 
Figure 34 – Apoptosis percentage in human monocytes. ....................................... 104 
Figure 35 – Reduced polarisation of CF M2 macrophages. ................................... 105 
Figure 36 – CFTR expression in M2 macrophages. ............................................... 106 
Figure 37 – Upregulation of IL-6 in M1 macrophages. ........................................... 107 
Figure 38 – CFTR expression in M1 macrophages. ............................................... 108 
Figure 39 – CFTR expression in CF M1 macrophages. ......................................... 109 
Figure 40 – Upregulation of TNF and IL-6 in CF M1 macrophages. ....................... 110 
Figure 41 – IRE1 inhibition reduces TNF and IL-6 secretion in CF M1 
macrophages. ........................................................................................................ 112 
Figure 42 – Increased levels of ROS and mROS in CF HBECs ............................. 120 
 xv
Figure 43 – Increased levels of ROS in CF M1 macrophages ............................... 121 
Figure 44 – Increased mitochondrial flux and glycolytic rates in CF monocytes. ... 123 
Figure 45 – Glycolytic function ............................................................................... 124 
Figure 46 – Increased mitochondrial flux and glycolytic rates in CF M1 macrophages.
 ............................................................................................................................... 126 
Figure 47 – mRNA expression of metabolic enzymes in M1 macrophages. .......... 127 
Figure 48– Mitochondrial function .......................................................................... 129 
Figure 49 – The IRE1-XBP1 pathway regulates metabolism in CF M1 
macrophages. ........................................................................................................ 130 
Figure 50 – Ivacaftor reduces the increased OCR levels in CF Macrophages. ...... 134 
Figure 51 – Orkambi partially reduces the increased OCR levels in CF macrophages.
 ............................................................................................................................... 138 
Figure 52 – CFTR modulators decrease the high OCR levels in CF HBECs ......... 142 
Figure 53 – No impact of CFTR modulators in the ECAR levels of CF HBECs ...... 144 
Figure 54 – The IRE1a-XBP1 signalling pathway of the UPR in CF. ..................... 150 
Figure 55 – Altered signalling pathways in CF macrophages ................................. 153 
 
Lists of tables 
Table 1 – Classification of the CFTR mutations ......................................................... 8 
Table 2 – Patients’ information and clinical data. ..................................................... 45 
Table 3 – Primer sequences .................................................................................... 49 
Table 4 – Seahorse Calculations ............................................................................. 56 
Table 5 – Table of resources .................................................................................... 60 
 1
 
Chapter 1 – Introduction 
1.1 Cystic Fibrosis 
 
1.1.1 The history and pathophysiology of cystic fibrosis 
 Cystic fibrosis (CF) is the most common life-limiting autosomal recessive 
genetic disorder, with a prevalence of one in 2,500 in the UK, and approximately with 
one in 25 individuals being carriers of the gene causing CF. While CF has been 
present in humans for more than a millennium, the disease was first mentioned in the 
medical literature around the middle ages, and it was associated with the presence of 
salty skin and damage to the pancreas in early child mortality [1]. It was not until 1938 
when Dr Dorothy H Andersen first described the disease in autopsies of children who 
died by malnutrition, where it was referred to as “cystic fibrosis of the pancreas” [2]. 
The chromosomal location of the CF gene was discovered in 1985 at position q31.2 
on the long arm of chromosome 7 [3]. Later in 1989, the CF gene was fully mapped 
and identified by Lap-Chee Tsui, John R. Riordan (Hospital for Sick Children, Toronto) 
and Francis S.Collins (University of Michigan). The gene was named the cystic fibrosis 
transmembrane conductance regulator (CFTR) (Figure 1) [4, 5]. The CFTR is a cellular 
membrane protein composed of 1,480 amino acids, that is part of the ATP-binding 
cassette (ABC) transporter family of membrane proteins, which main function is to 
transport ions through the cellular membrane [6]. 
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Figure 1 – History and median predicted survival age for patients with CF 
The median predicted survival age of patients with CF from 1930 to 2020 is shown by 
the black line. All primary treatments in CF are shown below the curve. The orange 
arrows show significant checkpoint discoveries. Data were taken from the CF 
foundation patient registry, 2017 Annual Data Report and from the UK CF patient 
registry, 2018 annual data report. 
 
Most human epithelial cells express the CFTR, including cells present in the 
respiratory, digestive, and urogenital tracts, which are mostly epithelial and secretory 
cells,  expressing the CFTR and, consequently, the most affected by CFTR mutations. 
Although it was believed that the CFTR was not present or functional in any other 
types of cells, there is now evidence to suggest that the opposite is the case. Studies 
have shown CFTR expression in different cells of the peripheral and central nervous 
system [7-11], cardiac cells [12, 13], red blood cells [14] and cells of the innate and 
adaptive immune systems [15-19]. In the case of epithelial and secretory cells, CFTR 
mutations result in abnormal chloride (Cl-), bicarbonate (HCO3-), and sodium (Na+) 
transport, in addition to the intracellular accumulation of misfolded proteins, in the case 
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of class II mutations [20, 21]. Patients with CF present frequent respiratory 
complications, resulting from (ASL) airway surface liquid dehydration derived from the 
abnormal ion channel function present in bronchial epithelial cells. Opportunistic 
pathogens exacerbate these recurrent pulmonary complications, the most common 
being Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus aureus (S. aureus), 
Haemophilus influenza (H. influenza) and Burkholderia cenocepacia (B. cenocepacia); 
these opportunistic pathogens promote an inflammatory process in the lung mainly 
caused by overwhelming secretion of pro-inflammatory cytokines, such as TNF, IL-1β, 
IL-6, IL-8 and IL-18 [22, 23]. The chronicity of these pulmonary infections underlines 
and dominates the clinical picture of patients with CF and, if not treated adequately, 
these can lead to further complications, by reducing pulmonary function and causing 
lung tissue destruction. A summary of the cellular pathophysiology seen in human 
bronchial epithelial cells (HBECs) with different CF mutations is summarised in Figure 
2. The different classes of mutations, based on their cellular phenotype, will be 
discussed in the next section. 
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Figure 2 – Cellular pathophysiology of CF HBECs 
In healthy HBECs the CFTR is typically produced and transported to the apical 
membrane, where it transports Cl- ions into the ASL. HBECs with CF mutations lack a 
proper flux of Cl- ions and this results in dehydration of the mucus layer, favouring 
bacterial infections. Different types of mutations lead to different types of CFTRs being 
produced. Refer to Table 1 for the classification of CF mutations.     
 
 Pancreatic insufficiency (PI) is another complication of CF, affecting around 
85% of patients with this genetic disorder [24]. The clinical manifestations of PI usually 
are present soon after birth; however, some patients develop these complications later 
in life [24]. Furthermore, early PI has been reported in patients with class I, II, III and 
VI mutations, commonly presenting with PI at birth [25]. It has been recently identified 
that pancreatic destruction starts in utero, and it has also been debated whether small 
molecule therapy will provide an adequate therapeutic option during pregnancy [26-
28]. Malnutrition is another complication of CF and patients typically struggle to gain 
weight, suffering a decline in both body mass index (BMI) and pulmonary function, due 
to the combination of pancreatic insufficiency and the hypermetabolic state of their 
cells [29, 30]. Arthritis is another complication that some patients with CF develop 
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throughout their lives. It is estimated that the prevalence of CF-associated arthritis 
(CFA) affects 1 in 10 patients with CF. [31]. In conclusion, CF is a multi-organ disorder, 
severely affecting the quality of life of patients who suffer from it, and which may lead 
to dramatic changes in their routine daily activities (Figure 3). 
 
 
Figure 3 – Organs affected in CF and common manifestations  
CF is a multi-organic disorder affecting several organs, with the most prominent being 
the lung, liver, intestines, pancreas, reproductive system and joints. One feature in 
common is that all the affected organs show inflammation.   
 
 6
1.1.2 CF Mutations 
 As mentioned previously, CF is a recessive genetic disorder meaning that 
people who suffer from this condition carry two copies of the mutated CFTR gene. The 
most common CF mutation, referred to as the F508 mutation, involves the deletion 
of three nucleotides in position 508, which results in the loss of the amino acid 
phenylalanine [4]. The F508 mutation is the most common alteration in European 
patients with CF, with more than 80% carrying at least one copy of the class II mutation 
and with the F508 being the most frequent mutation, this produces an abnormal 
CFTR channel, which is improperly folded and retained within the ER [32, 33]. More 
than 1900 different mutations have been identified in the CFTR gene at this point, with 
most of them causing CF [32]. CFTR mutations are classified into seven classes 
according to the specific characteristics of the CFTR protein or the messenger RNA 
(mRNA). Class I mutations include nonsense, frameshift and splice mutations, such 
as W1282X, which result in an unstable truncated mRNA, that is usually quickly 
degraded [34]. Class II mutations encompass mostly missense and amino acid 
deletion mutations, leading to a misfolded CFTR protein, followed by defective 
trafficking of the product. The F508 mutation is the most representative alteration of 
the class II spectrum, and it is also the most common CF mutation producing an 
abnormal CFTR channel, which is improperly folded and retained within the ER 
(Figure 2) [32, 33]. The class III mutations category includes the G551D, S549R and 
G1349D mutations, all of which are associated with a fully expressed membrane 
protein, but with defective channel regulation, thereby impeding normal ion trafficking 
through the cellular membrane [34]. An estimated 5% of patients with CF are carriers 
of at least one copy of the G551D mutation, which is the most common mutation in 
the class III spectrum. Moreover, patients with class III mutations strongly respond to 
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ivacaftor (VX-770), which is a small molecule that functions as a CFTR potentiator or 
channel opener, restoring CFTR functionality [34]. Class IV mutations are similar to 
class III mutations, in essence, as the CFTR is fully expressed and reaches the cellular 
membrane; however, there is a reduction in the channel conductance, in class IV 
mutations, rather than impaired gating, as described within class III mutations [34]. 
Class V mutations are characterised by insufficient production of CFTR protein, 
thereby reducing the ion flux, not because of defective cellular transcription or 
translation, but rather because of insufficient amount of protein being produced, 
frequently due to promoter or splicing site abnormalities [35]. In class VI mutations, 
there is decreased stability of the CFTR channel, leading to a reduction of the protein 
product. Class VI mutations can also cause activation of internalisation signalling 
pathways, resulting in decreased CFTR protein in the membrane and reduced surface 
expression [36]. Finally, class VII mutations were recently proposed, branching off 
from the class I category, with the same result as class I mutations, with no protein 
production, but with the unique characteristic of the lack of mRNA [37, 38]. A summary 
of the different CFTR classes is presented in  
Table 1 and includes the most common examples of each of the seven different 
classes. Patients with CF frequently present with a heterogeneous combination of 
different classes of CF mutations, with the F508 mutation being by far the most 
common mutation encountered. It is reasonable to hypothesise that the different class 
mutations will have different molecular and pathophysiological mechanisms, with the 
same outcome in terms of channel conductance, but with different and unique aspects 
regarding other signalling pathways, such as cellular stress, inflammation, metabolism 
and autophagy. 
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Table 1 – Classification of the CFTR mutations 
 
1.1.3 Understanding the current treatments in CF 
 Since the identification of CF, treatments have mainly been focused on 
managing the consequences of the disease, rather than the actual cause. In CF, the 
chronic infections and unresolved inflammation cause the production of a thick, dry 
and viscous mucus which predisposes to bacterial colonisation of the lung 
parenchyma [39]. In the clinic, mucolytic agents are currently being used to remove 
the thick mucus layer formed in the lumen of the lungs; in addition, because this mucus 
is characterised by high a concertation of DNA, special attention has been given to 
treating this complication of CF [39]. These increased DNA levels are mainly derived 
from abnormal neutrophilic infiltrations in the lungs, followed by an exaggerated 
inflammatory response, with increased levels of neutrophil extracellular traps (NETs) 
[40]. The formation NETs has been referred as an alternative mechanism by which 
neutrophils can get rid of bacteria, which will be explained in more detail in section 
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1.2.3, entitled “Monocytes, macrophages and neutrophils in CF” [41, 42]. The 
increased amounts of free DNA, which originate from NETs in patients with CF, have 
been associated with a decline in lung function [43-45]. Dornase alfa is a purified 
recombinant human deoxyribonuclease (DNase), which enzymatically hydrolyses the 
DNA present in the mucus of these patients, clearing the obstructed airways and 
helping to restore normal pulmonary function [46]. Another common mucolytic that has 
been used in the last decade, not only in CF but also in chronic obstructive pulmonary 
disease (COPD), is N-acetylcysteine (NAC) [47]. While treatment with NAC is safe in 
patients with CF, some controversies exist relating to NAC efficacy in the clinic [48-
50]. Hypertonic saline (HS) is a cheap, safe, effective and commonly used additional 
therapy in CF, which helps mucociliary clearance by rehydration of the mucus present 
in the airway surfaces. HS is efficient in reducing the number of pulmonary 
exacerbations, by 56% compared to the control group, when used in combination with 
intravenous (IV) antibiotics [51]. Mannitol is another compound which helps in the 
restoration of a normal airway liquid surface. Mannitol is a sugar alcohol which helps 
in the clearance of airway mucus by changing the osmotic gradient, leading to 
rehydration of the airway surface [47]. Correct intervention with mannitol aids in the 
recovery of FEV1% and in the reduction of pulmonary exacerbations in patients with 
CF [52, 53]. 
Antibiotics are commonly used in the clinic to treat patients with CF, in different types 
of situations, depending on the cohort of patients being treated and the pathogens 
which could potentially, be present during the infection. Antibiotics are mainly used in 
the eradication of early infections and to control chronic bacterial infections; however, 
they are also often used to control pulmonary exacerbations and prophylactically to 
prevent infections developing in patients with CF. The lung microbiome constitutes an 
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essential aspect in the pathogenesis of CF [47]. For instance, during the early ages of 
this disease, the most frequent pathogen cultured from the lungs of young children is 
S. aureus, which represents the most prevalent pathogenic bacteria in paediatric 
cohorts [54, 55]. Interestingly, the composition of the lung microbiome changes during 
the lifetime of patients with CF. After the age of 10, colonisation with P. aeruginosa 
progressively increases until it is the primary pathogen present in the lungs of these 
patients, while the prevalence of S. aureus is reduced in the adult cohort (Figure 4) 
[54, 56].  
 
Figure 4 – Prevalence of respiratory pathogens, by age, in respiratory cultures 
of patients with CF 
Data from Cystic Fibrosis Foundation Patient Registry, 2004 annual data report to the 
centre directors [56] © Cystic Fibrosis Foundation, 2005. 
 
P. aeruginosa is the most common pathogen found in adults with CF, with an 
estimated 80% of the patients being infected with this pathogen, which is generally 
associated with clinical complications [54]. While antibiotics have helped in the 
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treatment of CF, antimicrobial resistance has become a severe problem in the 
treatment of CF. Antimicrobial resistance needs to be taken very seriously in CF 
because it is creating a significant challenge in the eradication of pathogens during 
respiratory infections [57]. 
 Inflammation, which will be explained in detail in section 1.2, represents a 
significant challenge in CF, and, while not completely understood, there are studies 
which help to shed light on the mechanisms behind this problem [30, 58, 59]. Non-
steroidal anti-inflammatory drugs (NSAIDs) are commonly used in CF, to treat the 
symptoms related to the inflammation, and, when necessary, corticosteroids are used 
to control the excessive inflammation presented by patients with CF [47]. Macrolides 
are efficient in controlling the inflammation in patients with CF, in particular, 
azithromycin, which is regularly used in the clinic [60, 61]. Patients treated with 
azithromycin, over a six months period, showed reduced incidence of the S. aureus 
pathogen, as well as a significant reduction in pulmonary exacerbations [62]; however, 
it has been shown that some pathogens in patients with CF, such as P. aeruginosa, 
can acquire resistance to macrolides, which will represent an even more serious 
challenge in the future [63].  
While all the treatments mentioned previously were focused towards 
ameliorating the consequences of the disease, rather than fixing the actual root of the 
problem, which is the mutated CFTR, several novel small-molecule therapies are 
currently available for the treatment of CF. In January 2012 ivacaftor (VX-770), 
developed by Vertex pharmaceuticals, under the trade name of Kalydeco, was the first 
small molecule therapy approved by the FDA for patients with CF. Ivacaftor is a CFTR 
potentiator or channel opener, restoring the CFTR functionality and improving the 
abnormal ion flux [64]. Ivacaftor is an effective therapy for patients with class III 
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mutations, initially restricted only to patients with G551D mutations but most recently 
shown to be efficient in other mutations, such as non-Gly551Asp and R117H class IV 
mutations [65-67]. Several studies have shown that ivacaftor significantly restores 
predicted FEV1% by more than 10%, decreases sweat chloride and increases 
weight/BMI, in patients with CF with at least one G551D mutation [67]. A combination 
drug under the brand name of Orkambi, composed of lumacaftor (VX-809) and 
ivacaftor (VX-770), a channel corrector and potentiator respectively, has been used to 
treat patients with two copies of the F508 mutation, with some controversial results 
[68, 69]. While the FDA approves Orkambi and it is licenced for its use in the UK, the 
National Institute for Health and Care Excellence (NICE), initially rejected its use, due 
to cost-inefficient results and the lack of long-term data; however, after negotiations 
with the pharmaceutical company Vertex, it is now available in the UK. While some 
clinical trials have shown a modest but still significant improvement of the predicted 
FEV1%, which ranged from 4 to 6.7%, and a reduction in pulmonary exacerbations by 
~35%, there was no significant reduction in sweat chloride nor an increase in the 
weight/BMI ratio [70, 71]. One of the most significant problems with Orkambi is the 
prevalence of adverse effects in patients treated with this drug combination [72]. In a 
retrospective cohort study, 39.7% of patients who started treatment with Orkambi 
reported adverse effects related to the drug [73]. In another study, it was reported that 
51% of the subjects, under the double therapy, suffered respiratory adverse effects, 
and 30% of the participants discontinued the treatment [74]. Tezacaftor, a new channel 
corrector, is now used in combination with ivacaftor for the treatment of patients 
homozygous for the F508 mutation. The combination of tezacaftor and ivacaftor has 
shown to be efficacious in the treatment of patients with CF, showing similar results 
than its predecessor Orkambi but without a significant increase in the adverse effects 
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shown by Orkambi [72]. The most recent addition of VX-445, a channel corrector, in 
combination with tezacaftor and ivacaftor, which is referred as triple combination 
therapy, significantly increased the predicted FEV1% by 13.8% in patients with a single 
copy of the F508 mutation [75-77]. Impressively, F508 homozygous patients 
incorporating VX-445 to their tezacaftor and ivacaftor regimen showed a significant 
11% increase in their predicted FEV1%, and both groups reported a reduction in sweat 
chloride [75, 76]. Several other compounds are under development for the treatment 
of CF, which are being developed by the pharmaceutical companies Vertex, 
Proteostasis Therapeutics and Galapagos [78] . A timeline of the CF drugs developed 
can be seen in Figure 1. 
Finally, it is important to mention the recent development of gene therapy as a 
potential cure for CF. Initial investigations have demonstrated that lentiviral vector 
delivery might be a suitable option to “cure” CF, or at least to offer a cure for some of 
the lung complications [79]. Another promising future “cure” for CF, with potentially 
less off-target effects than lentiviruses, are genomically guided therapies or gene 
editing, with the use of powerful tools, such as CRISPR-Cas9, which potentially 
represent a complete correction of the mutated CFTR [80]. It is fascinating how gene 
editing might develop into a powerful correction therapy or “cure” in the near future. 
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1.2 Inflammation in CF 
 
1.2.1 Inflammation in human bronchial epithelial cells  
Inflammation is a severe complication in CF and management of this problem 
is a crucial factor in achieving an excellent clinical prognosis. The immune system is 
the principal regulator of the inflammatory response, and several cells of the innate 
immune system are intrinsically affected by CF mutations [30, 59]. While lung 
inflammation in CF remains unclear, it is known that bronchial epithelial cells play an 
essential role in the abnormal inflammatory response seen in patients with CF. It has 
been shown that HBECs, affected by CF mutations, have an abnormal inflammatory 
response [81]. CF HBECs, stimulated by the pro-inflammatory cytokines, TNF and IL-
1 produce significantly higher amounts of IL-6 and IL-8 compared to wild type (WT) 
and CF corrected HBECs [82]. A similar response was observed in a different study, 
when CF cells were challenged with P. aeruginosa producing significantly higher 
quantities of IL-8, IL-6 and GM-CSF [83]. These observations are consistent with the 
clinical complications observed in patients with CF, which show raised levels of IL-8 
and IL-6 during bacterial infections [22, 23]. Similar findings were observed in BECs 
obtained from children with CF <5 year old, where significantly higher amounts of IL-
8 mRNA were detected in CF  infants compared with control infants [84]. While several 
limitations exist in all studies mentioned earlier, they consistently show an 
exaggerated inflammatory response. The CFTR can be chemically inhibited by the 
CFTRinh-172, and this potent inhibitor has been able to mimic the abnormal 
inflammatory response seen in CF [85]. HBECs exposed to CFTRinh-172, for more 
than 72, hours showed a significant increase in IL-8 under basal conditions and 
increased activity in NF-B after TNF and IL-1stimulation [85]. Another vital player 
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during the inflammatory response is reactive oxygen species (ROS), which play a 
significant role in the clearance of bacteria and are also capable of influencing the 
inflammatory response [86]. Oxidative stress has been shown to be increased in 
HBECs with CF mutations and it has been associated with an increased number of 
apoptotic cells and high levels of IL-8 and IL-6 [86, 87]. Furthermore, the chronic 
inflammatory environment present in the lungs of patients with CF can trigger an 
expansion of ER Ca2+ stores, directly contributing to the exaggerated inflammatory 
response [88, 89]. It would be of interest to investigate the interaction between 
bronchial epithelial and immune cells to discern whether these interactions contribute 
to the unresolved chronic inflammation seen in patients with CF.      
 
1.2.2 Animal models of CF and inflammation 
The excessive inflammation present in patients with CF has been replicated in 
several animal models helping us to understand the underlying mechanisms behind 
this abnormal inflammation and its relation to CFTR mutations. Animal models are 
fundamental strategies to achieve a better understanding in the pathophysiology of 
diseases. There is an extensive repertoire of different animal models with a CF like-
disease such as, mouse, rat, sheep, pig, ferret and zebrafish which, to a certain extent,  
resembles the complications seen in CF [90]. 
The first CF animal model created was a mouse, and it was generated soon 
after the identification of the CFTR gene. Today, there are more than 14 different CF 
mouse models which resemble some of the aspects seen in CF [90]. While mice 
models provide us with new insights for a better understanding of CF, certainly these 
models present certain limitations in the study of CF, as some models have shown an 
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alternative conductance of Cl- which compensates the lack of CFTR functionality in 
some organs [91]. This study described an alternative conductance of Cl- that was 
only detected in lung and pancreatic epithelial cells, which displayed a moderate 
disease severity while being completely absent in the intestinal tract, where the 
severity of the disease was more pronounced [91]. Later, it was found that this 
alternative conductance of Cl- was undoubtedly due to the mixed genetic background 
of the mice and, indeed, the model was improved by creating an inbreed congenic 
CFTR-knockout mouse [92]. This new CF mouse model presented spontaneous and 
progressive lung disease, including defective mucociliary transport, idiopathic 
pulmonary fibrosis, enhanced immune cell infiltrations and severe inflammation. 
Interestingly, this CF mouse model developed a chronic inflammatory disease in the 
absence of pathogenic organisms and, also, mice were more susceptible to P 
aeruginosa infections compared to the WT control mice [92-95]. Consistent with the 
levels of pro-inflammatory cytokines seen in patients with CF, CF mice also presented 
increase levels of several pro-inflammatory cytokines including TNF, IL-1, IL-6 and 
IL-8 [94, 96]. The cells that are found mainly in the lung of CF mice are macrophages 
and neutrophils, which are discussed in the next section and, indeed, contribute to the 
high degree of inflammation seen in CF [96]. The abnormal inflammation seen in 
CFTR-knockout mice is not restricted to the respiratory and intestinal tract, as it has 
been reported chronic inflammation and infiltration of immune cells in the liver and 
pancreas of these CF mice, causing damage and destruction of the tissue [95]. 
Another alternative and interesting CF mice model is the β-ENaC model, which 
develops a similar lung phenotype shown by patients with CF [97]. This model was 
created by overexpressing the β subunit of the epithelial Na+ channel (ENaC), which 
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is overactive in CF, and has as a consequence increased Na+ transport mimicking the 
CF phenotype [97, 98]. 
The controversies presented by CF mouse models led to the development of a 
CF pig model, as these animals share some anatomical and morphological features 
seen in humans [99]. The first pig model was a CFTR-Knockout, CFTR-/-, created by 
homologous recombination in primary fibroblast followed by somatic cell nuclear 
transfection [99]. New-born CFTR-/- piglets present intestinal and pancreatic 
abnormalities similar to those seen in humans, with inflammation and infiltration of 
immune cells into the affected tissues [99]. Furthermore, at birth these piglets did not 
present any abnormality in airway epithelial cells or mucosal glands, at first sight; 
however, these animals rapidly developed a severe lung infection and inflammation 
with a more severe phenotype when compared to humans [90, 99, 100]. When CFTR-
/- piglets were challenged to S aureus, the most common pathogen present in children 
with CF, piglets with CFTR mutations failed to eradicate this bacterial infection causing 
chronic infection and inflammation with further destruction of lung tissue [100]. The 
first CF mouse model reported a residual CFTR conductance, and the later 
CFTRΔF508/ΔF508 pig model also reported this residual function with about 6% of WT 
function [101]. New-born CFTR-/- piglets usually present gastrointestinal abnormalities 
including, pancreatic destruction, bowel obstruction and early biliary cirrhosis, and 
while lungs appeared to be healthy after birth, this organ also develops a rapid 
inflammation which evolves into a severe lung disease [101]. Similar to pigs, ferrets 
with CFTR mutations also develop spontaneous lung inflammation, pancreatic and 
gastrointestinal abnormalities within the first weeks after being born, showing 
increased levels of IL-8 and TNF [102, 103]. One study demonstrated that new-born 
CF ferrets were unable to eradicate P aeruginosa infections compared to their WT 
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counterparts; also, they showed a deficient innate immune system and pulmonary 
hyper-inflammation [104]. It was recently demonstrated that ferrets homozygous 
CFTRG551D/G551D could be rescued by administration of ivacaftor, ivacaftor, in utero and 
after birth [105]. administration of ivacaftor in utero in CFTRG551D/G551D ferrets corrects 
the abnormal formation of the vas deferens and epididymis, augments growth and 
partially recovers the normal pancreatic function [105]. Postnatal administration of 
ivacaftor improves lung function and helps in the reduction of bacterial infections, and 
withdrawal of the treatment leads to the development of CF lung disease [105]. The 
CF sheep model also corroborates certain features present in the other models of CF, 
with the most common being pancreatic destruction, gastrointestinal abnormalities, 
absence of the vas deferens, and obstruction of the epididymis; however, an abnormal 
lung phenotype was not correlated with mutations in the CFTR gene in this model 
[106]. A feature of this, and other models of CF, is the early infiltration of immune cells 
followed by an abnormal inflammatory process with eventual damage and destruction 
of the pancreatic tissue [90, 106]. Pancreatic destruction is another common 
characteristic seen in CF, which has been replicated in a CF zebrafish model. In this 
unique model of CF, CFTR-/- zebrafish larvae frequently presented higher numbers of 
neutrophilic infiltration in the pancreas with further damage to the organ [107]. In a 
similar study, it was found that macrophages are crucial for the development of the 
pathogenic bacteria B cepacia, as this pathogen was unable to proliferate in zebrafish 
depleted of macrophages [108]. It is interesting how different models of CF coincide 
in similar phenotypic abnormalities which are also present in humans, making these 
models a valuable tool to investigate the origin of his disease and to test new drug 
compounds for the treatment and potential cure of this disease. 
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1.2.3 Monocytes, macrophages and neutrophils in CF 
As seen in the previous sections, inflammation is a common feature in CF. 
While epithelial cells play an important role in the pathogenies of inflammation, 
certainly immune cells orchestrate the initiation and the restoration of the inflammatory 
response. The immune system is subdivided into two branches, known as the adaptive 
and the innate immune system, the former composed mainly by T, B and natural killer 
(NK) cells and the later by basophils, eosinophils, neutrophils, monocytes and 
macrophages [109]. While both branches of the immune system are fundamental parts 
for the clearance of any infection, today there has not been a direct relationship 
between CFTR mutations and abnormal activity of the adaptive immune system. 
Adaptive immune cells are crucial in the eradication of any infection and, in fact, a 
subpopulation of T cells, Th17, are largely found in the submucosa layer of the lung of 
patients with CF [110]. A correlation between Th17 cells and neutrophil counts in these 
patients, suggesting that it might be the abnormal amount of neutrophils what is 
causing the Th17 cells to be recruited to the site of the infection [110]. It is uncertain 
whether the cells of the adaptive immune system are affected by CF mutations, and 
further research is encouraged to explore this alternative.  
In the case of the innate immune system, there is abundant evidence 
suggesting a direct correlation between CFTR mutations and an intrinsic defect in 
monocytes, macrophages and neutrophils [18, 19, 30, 59, 108, 111-114]. Monocytes 
are phagocytic cells that originate from the bone marrow with the capacity to be 
differentiated into macrophages and dendritic cells, which are professional antigen-
presenting cells (APC). Some reports demonstrate that monocytes and macrophages, 
from CF children, present downregulation of the surface markers CD14 and HLA-DR 
with deficient phagocytosis [115]; however, these findings have been challenged by 
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other reports showing that there is no difference in monocyte subpopulations [18, 116]. 
Expression of the surface markers M-CSF, TLR4, IL-4R IL-13R1, TIMP-1 and Cox-
2, were shown to be upregulated in CF monocytes, demonstrating that CFTR 
mutations intrinsically affect monocytes from patients with CF [18]. Interestingly TLR4 
has been reported to be consistently upregulated in both monocytes and 
macrophages from patients with CF and it was not related to pulmonary infections [17, 
18, 117]. In another study, IL-8 was shown to be upregulated in CF monocytes after 
an LPS challenge, and this IL-8 overexpression was not associated with TLR4 
overexpression but, rather, to an alternation in MAPK signalling [118]. The importance 
of CFTR expression in myeloid cells was demonstrated in a conditional KO mice 
model, where only myeloid-derived cells suffer from the lack of CFTR [119]. Normally, 
these conditional myeloid CFTR KO mice did not show any differences compared to 
WT mice; however, when these mice were challenged to bacterial pathogens in the 
lung, these mice displayed a significantly higher inflammatory response and 
decreased survival rate compared to WT mice [119].  
When monocytes are recruited to the site of infection or inflammation, these 
myeloid cells can be differentiated into classically activated macrophages, pro-
inflammatory (M1), or alternatively activated macrophages, anti-inflammatory (M2) 
[120]. As monocytes differentiate toward macrophages, their ER is expanded, and 
their size becomes expanded, providing these unique cells with a greater capacity to 
promote inflammation and phagocytosis. Other types of macrophages also exist, 
known as tissue-resident macrophages. While monocytes derived macrophages 
originate from the bone marrow, tissue-resident macrophages are derived either from 
the yolk sac or foetal liver and reside in specific tissues with unique characteristics 
[121, 122]. Not only have different types of tissue-resident macrophages been 
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characterised, but different subtypes of monocyte-derived macrophages, such as 
M2a, M2b, M2c and M2d, have also been described in the literature [123, 124]. In CF, 
alveolar macrophages are partially responsible for the high degree of airway 
inflammation and it is known that patients with CF present a large number of 
macrophages in the lung, with high concentrations of neutrophils as well [113, 125]. 
Increased expression of the pro-inflammatory cytokines IL-1 and CCL-2 was reported 
in alveolar macrophages from CF mice stimulated with the TLR4 agonist LPS, while 
the expression of IL-10 was decreased in these mice [126]. Interestingly, azithromycin 
efficiently reduced the exaggerated inflammatory response decreasing the high levels 
of TNF, IL-1 and CCL-2 in M1 macrophages [126]. Furthermore, this study reported 
that both M1 and M2 macrophage polarisation was significantly increased in alveolar 
and peritoneal macrophages from CFTRΔF508/ΔF508 mice [126]. Although, both M1 and 
M2 macrophages are increased in CF mice, the opposite was reported in human 
macrophages with no difference in the polarisation of M1 and a significant decrease 
in the polarisation of M2 [19, 30]. A different study reported a significant upregulation 
of M2 macrophage polarisation in patients with CF at baseline, meaning that they 
pushed monocytes to macrophages right after the blood isolation, and downregulation 
of M1 macrophages 48 hours after the polarising stimulus [111]. The discrepancies of 
these studies might originate in the different surface markers used for macrophage 
characterisation, the method for macrophage polarisation and, ultimately, in the 
isolation method for these monocytes. Certainly, monocytes and macrophages 
harbouring CFTR mutations present with intrinsic abnormalities affecting their cellular 
functions and contributing towards an abnormal inflammatory response.  
Neutrophils are also important players in the pathogenesis of CF and these 
multinucleated cells are reported to be increased in the lung of patients with CF [22]. 
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It was recently reported that delayed apoptosis of CF neutrophils increased NET 
formation in the lungs of patients with CF, helping to explain that certain characteristics 
of CF neutrophils are not entirely related to inflammation, but rather to an intrinsic 
cellular defect mainly associated with CFTR mutations [59]. Furthermore, the 
stimulation of macrophages with NETs induced the production of TNF and IL-8, and 
both cytokines were significantly higher in CF macrophages compared to HC 
volunteers [59]. In the clinic, the levels of TNF and IL-8 have shown a positive 
correlation with disease progression and it is known that the high levels of these 
cytokines can induce the infiltration of neutrophils in the lung [127, 128].  
Inflammation is certainly a problem in CF and the underlying cause of this 
abnormal process is not solemnly due to a single factor but, rather, to a combination 
of different environmental and intrinsic defects present in cells with CFTR mutations. 
For that reason, it is critical to understand the underlying impact  of CFTR mutations 
in different immune cells and their interaction with other cells.  
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1.3 ER Stress and the Unfolded Protein Response 
 
1.3.1 The UPR signalling pathways 
The unfolded protein response (UPR) is a conserved and unique cellular 
mechanism, which is present in mammalian and yeast cells [129]. The UPR is 
activated under cellular stress, with endoplasmic reticulum (ER) stress being one of 
the principal activators of this unique mechanism [129, 130]. The UPR can be 
activated when either unfolded or misfolded proteins are detected, causing activation 
of three classes of ER-resident proteins, referred to as inositol requiring enzyme 1 
(IRE1), double-stranded RNA-activated protein kinase (PKR)-like ER kinase (PERK), 
and activating transcription factor 6 (ATF6) [129]. It is essential to mention that UPR 
activation can be induced by several other stimuli such as, oxidative stress, starvation, 
inflammatory cytokines and pathogens, making the UPR a complex signalling pathway 
[131-134]. Another player, in the regulation of these three UPR ER-resident proteins, 
is the heat shock protein binding immunoglobulin protein (BiP), also known as HSPA5. 
With the accumulation of misfolded proteins in the lumen of the ER, BiP, which is 
generally bound to IRE1, PERK and ATF6, is dissociated from these proteins and 
sequestered by the misfolded proteins, with subsequent activation of the UPR 
signalling pathway [129]. The three primary arms of the UPR work in concert to re-
stablish normal cellular function decreasing cellular stress, and when this is not 
possible, to induce cellular apoptosis. 
The most characterised arm of the UPR is IRE1 a dual ER transmembrane 
protein, with both kinase and RNase activity, that is found in two isoforms, IRE1 and 
IRE1, with IRE1 being the most common isoform. The oligomerisation of IRE1 
causes phosphorylation of its kinase subunit, with subsequent activation of its RNase 
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domain favouring the degradation of specific RNAs in a process known as regulated 
IRE1-dependent decay (RIDD) [130, 135]. This particular process is known to interact 
with more than 120 different RNAs, causing the degradation of these transcripts or, in 
particular cases, the modification of them [135]. The mRNA of a transcription factor 
known as X box-binding protein 1 (XBP1) can be directly affected by the RNase 
domain of IRE1 and, when active, it causes a translational frameshift removing a 26 
nucleotide intron producing a shorter isoform referred to as XBP1 spliced (XBP1s) 
[136, 137]. XBP1s is a potent pro-survival transcription factor involved in several 
cellular regulatory mechanisms including metabolism, inflammation and autophagy, 
dynamically regulating other ER stress-responsive genes [138-141].  
The next arm of the UPR is ATF6, which is found in two different isoforms 
ATF6 and ATF6 with some evidence demonstrating that ATF6 is a negative 
regulator of ATF6 [129, 142]. After detecting cellular stress, ATF6 is moved to the 
Golgi apparatus where it is proteolytically cleaved releasing a cytoplasmic fragment 
that is further translocated into the nucleus directly upregulating XBP1, CHOP and 
several chaperone proteins [129, 142].  
The last arm of the UPR is PERK, which has been identified for its kinase 
activity but lacking the unique RNase domain present in IRE1. In a similar manner to 
IRE1, removal of BiP from the luminal domain of PERK induces protein dimerisation 
followed by auto-phosphorylation and eventual activation of the ER transmembrane 
protein [129, 143]. PERK activation is followed by a complex and dynamic pathway 
that regulates protein synthesis via eukaryotic initiation factor 2 (eIF2) [144]. When 
PERK is activated, it causes phosphorylation of eIF2which, in turn, halt protein 
synthesis helping to reduce the ER protein load to reduce cellular stress [143, 144] 
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eventually. Paradoxically, the activation of eIF2 also induces the production of 
activation transcription factor 4 (ATF4), a potent transcription factor which is involved 
in the regulation of genes related to metabolism, autophagy and cellular oxidation 
[144]. Importantly, when cells are exposed to chronic ER stress, ATF4 induces the 
expression of C/EBP homologous protein (CHOP), and accumulation of CHOP has 
been associated with apoptosis [145, 146]. Activation of eIF2 is negatively regulated 
by growth arrest and DNA damage-inducible protein (GADD34). Induction and 
activation of GADD34 can be achieved by CHOP and ATF4, functioning as a 
phosphatase of eIF2, thereby restoring protein synthesis to its normal state and 
downregulating PERK activation [129, 147]. Furthermore, there is some evidence 
suggesting that PERK can regulate the oxidative response through activation of 
nuclear factor erythroid 2-related factor 2 (Nrf2), which is known to be a strong 
regulator of the antioxidant response [148, 149]. The UPR signalling pathway has 
been summarised in the next diagram (Figure 5). The UPR is versatile and complex 
signalling pathway and it has been demonstrated to strongly regulate the inflammatory 
response as it will be explained in the next section. 
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Figure 5 – The UPR signalling pathway 
BiP detects unfolded protein within the ER, activating ATF6, IRE1, and PERK. ATF6 
activation leads to the production of ATF6f, which upregulates UPR target genes. IRE1 
is auto-phosphorylated, inducing mRNA degradation through RIDD. The RNase 
domain of IRE1 induces the unconventional splicing of the transcript XBP1 and 
produces XBP1s. PERK activation induces phosphorylation of eIF2 selectively 
upregulating ATF4 inducing UPR target genes, including GADD34 and CHOP. 
 
1.3.2 Inflammation and the UPR 
Inflammation is one of the main consequences of bacterial infections, tissue 
damage, autoimmunity or autoinflammation. Autoinflammation can be described as a 
self-directed inflammation with a direct influence of the local tissue environment 
followed by activation of the innate immune system, causing tissue damage and 
cellular death [150]. Autoinflammation can also be induced by intrinsic cellular insults, 
normally caused by genetic mutations, generating a low-grade chronic inflammation 
responsible in priming and, eventually, exacerbating the inflammatory response [30, 
151, 152]. This low-grade chronic inflammation can be caused by the accumulation of 
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misfolded proteins in the ER, hence activating the UPR. It has been shown that the 
IRE1 arm of the UPR regulates the transcription of several pro-inflammatory 
cytokines, such as TNF, IL-1, IL-6 and IFN- [151, 153, 154]. It is known that 
activation of TLR4 and TLR2 can induce the activation of the IRE1-XBP1 signalling 
pathway inducing the transcription of the pro-inflammatory cytokines TNF and IL-6 
(Figure 5) [133, 151]. Furthermore, XBP1s is indeed recruited to the promoter region 
of TNF and IL-6 inducing transcriptional activation of these two cytokines [151].  
Similarly, ATF4 was shown to interact with IL-6 binding region, promoting 
upregulation of IL-6 in macrophages [155]. Activation of main signalling pathways 
necessary for the production of pro-inflammatory cytokines, such as NF-B, can work 
in synergy with the IRE1-XBP1 signalling pathway inducing an exaggerated 
inflammatory response [30, 133, 151]. The UPR has been shown to induce cellular 
stress and inflammation in several immune-related disorders, particularly in 
autoinflammatory disorders [156]. The autoinflammatory condition tumour necrosis 
factor receptor-associated periodic syndrome (TRAPS), is a genetic disorder mainly 
characterised by recurrent periodic fevers and uncontrolled episodes of inflammation 
[157]. TRAPS is characterised by intracellular accumulation of tumour necrosis factor 
receptor 1 (TNFR1), causing ER stress followed by activation of the UPR [158, 159]. 
Cells with TRAPS mutations showed significantly higher levels of XBP1s, PERK and 
ROS, showing an exaggerated response to LPS with further secretion of TNF, IL-6 
and IL-1 [158, 159]. IL-1 is an important inflammatory cytokine which is normally 
elevated in patients suffering from autoinflammatory conditions. This cytokine is 
mainly regulated by the NLR Family Pyrin Domain Containing 3 (NLRP3). The NLRP3 
is a conserved innate immune mechanism created to detect pathogen-associated 
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molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), 
ultimately activating the pro-inflammatory cytokines IL-1 and IL-18 [160].  
ER stress and the UPR signalling pathway have been directly involved in the 
activation of the NLRP3 inflammasome with further production of IL-1 [161-163]. The 
NLRP3 responds to ER stress and induces the production of IL-1 independently of 
IRE1 and XBP1 [161]. In another study, it was shown that TXNIP, a protein-coding 
gene induced by IRE1, is an important inducer of IL-1 and ROS and, silencing of 
TXNIP led to reduction of IL-1 with a further reduction of inflammation [163, 164]. 
Furthermore, caspase-2 and BID were shown to be fundamental in the classical 
activation of the inflammasome and the secretion of IL-1 [163]. A recent study 
indicates that the RNase activity of IRE1 is an important player in the assembly of 
the NLRP3 and its eventual activation [154]. This study shows that inhibition of IRE1 
RNase domain diminishes NLRP3 activity, reducing caspase-1 activation and IL-1 
[154]. While the production of IL-1 is directly affected by inhibition of IRE1certainly 
IL-18 is not, suggesting that the NLRP3 is a complex mechanism that can be 
influenced by more than one signalling pathway. ER stress, followed by UPR 
activation, has been detected in synovial fibroblast and PBMCs from patients with 
rheumatoid arthritis (RA) [133]. Macrophages and neutrophils from myeloid-
conditional IRE1-/- mice showed a reduction of pro-inflammatory cytokines with 
amelioration in the clinical disease score after inducing arthritis, compared to WT mice 
[165]. Furthermore, inhibition of IRE1RNase domain with 48C, in the same mice, 
showed a reduction in the inflammation after inducing arthritis [165]. GSK-3 can also 
induce IL-1through IRE1activation but independent of XBP1 [166]. Moreover, 
inhibition of GSK-3 selectively downregulated IL-1 gene expression, while inhibition 
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of IRE1with STF083010 only inhibited TNF production without any effect in IL-1 
[166].  
Cigarette smoke can also stimulate multiple signalling pathways in airway 
epithelial cells generating ROS, ER stress and activation of the UPR [167, 168]. 
Several UPR related proteins including BIP, calreticulin, ATF4 and NRF2, were 
upregulated in smokers compared to non-smokers [168]. In a different study, it was 
demonstrated that ATF6 mediates the regulation of the pro-inflammatory cytokines 
TNF and IL-6 during ischemia-reperfusion [169]. Liver macrophages exposed to 
ischemia showed induction of ER stress with an emphasis in ATF6 upregulation. 
Modulation of ER stress during this ischemia-reperfusion model by ATF6 siRNA, 
decreased the level of inflammation in the liver, protecting the organ from ischemia-
reperfusion injury [169]. The UPR plays an important role in the regulation of the 
inflammatory response; therefore, a better understanding of this signalling pathway is 
encouraged.   
 
1.3.3 CF and the UPR 
ER stress and the UPR are essential players in the pathogenies of different 
diseases as shown in the previous sections. Some reports show an abnormal UPR 
activation in cells with CF mutations [170]. In CF there is an abnormal mucus formation 
which favours the colonisation of bacterial pathogens in the lung. Furthermore, when 
airway epithelial cells are exposed to supernatants from this mucus material from 
patients with CF, the ER becomes enlarged with an increased capacity to sequester 
Ca2+ [88]. This ER expansion is an innate immune response to chronic infections and 
inflammation, which is regulated by several ions including Ca2+ [88]. This ER 
 30 
enlargement may potentially induce cellular stress and activation of the UPR. After 
exposure to the supernatant from the mucus material, CF HBECs were shown to be 
hyperinflammatory with higher levels of IL-8 production compared to non-CF cells [89]. 
This hyperinflammatory response was mediated by an increased Ca2+ flux a result 
from an enlarged ER in these epithelial cells [89]. In a different study, the ER 
expansion and the increased Ca2+ flux in HBECs were associated with increased 
levels of XBP1. Isolated HBECs from patients with CF, with inflamed or infected lungs, 
showed an increased expression in XBP1s [171]. This finding was corroborated in 
mouse models and cell lines, showing the importance of XBP1s in the enlargement of 
the ER and production of IL-8 [171].  
Atypical activation of the UPR was reported in CF with an upregulation of the 
IRE1-XBP1 pathway and a lack of induction of PERK-eIF2 [172]. In this study, it 
was shown that XBP1u and XBP1s were both upregulated in immortalised CF HBECs, 
CF lung tissue and PBMCs, while the PERK–eIF2pathway was downregulated only 
in the CF HBECS [172]. Furthermore, MAPK p38 is overactive in CF HBECs inducing 
the production of IL-6, which can be reduced by inhibiting p38 MAPK with SB203580 
[172]. In a different study, TNF and IL-6 were significantly upregulated in alveolar 
macrophages from patients with CF under basal conditions and after LPS stimulation 
[113]. The overexpression of XBP1s was correlated with the exaggerated 
inflammatory response, as inhibition of XBP1s with the inhibitor 48C reduced 
cytokine production ameliorating the inflammatory response [113]. Interestingly XBP1-
KO in the monocytic-like cell line THP-1, completely abrogated the production of TNF 
at both the mRNA and cytokine level, even after LPS stimulation, while IL-6 was 
significantly downregulated [113]. XBP1 plays an essential role in the pathogenesis of 
CF, modulating inflammatory pathways in this genetic disorder. One study 
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demonstrated that overexpression of F508-CFTR in human airway cells is 
associated with the amount of XBP1s produced by the cells [173]. In this study, the 
authors overexpressed different levels of F508-CFTR in the Calu3 cell line. While 
only the cell line with the highest expression of F508-CFTR showed a significantly 
higher amount of XBP1s under basal conditions, all the cells expressing F508-CFTR 
showed increased XBP1s production after induction of UPR activation with 
tunicamycin [173]. This finding supports the idea that undetected low-grade chronic 
ER stress could prime the cells towards an exaggerated response after a second 
challenge. ATF6 is activated in cells harbouring CFTR mutations [174]. F508-CFTR 
expressing cells showed an increase in BiP and activation of ATF6, demonstrated by 
ATF6 fragmentation [174]; however, in a different study, this finding was challenged 
showing that ATF6 is downregulated in CF cell lines and bronchial brushings from 
patients with CF compared to HC controls [175]. The authors also demonstrated that 
overexpression of miRNA-221 in CF cells downregulates ATF6 expression [175]. 
While the UPR plays an essential role in CF, more research is needed to elucidate the 
consequences of its activation. 
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1.4 Cellular Metabolism 
 
1.4.1 Glycolysis and the Krebs cycle 
While this section will cover the significant aspects of glycolysis and Krebs 
cycle, by no means will cover every single aspect of cellular metabolism as this topic 
can be overwhelming and extensive. Metabolism is the process of converting food into 
energy, better known as adenosine triphosphate (ATP), by a series of complicated 
biochemical reactions [176]. The three primary sources of energy for mammalian cells 
are known to be carbohydrates, proteins and fatty acids, which are broken down by a 
series of different enzymes with the final goal of producing ATP [176]. While fatty acid 
and protein metabolism, also known as oxidation and protein catabolism, are 
regulated by different molecules, they both produce at the end pyruvate that under 
normal circumstances enters the Krebs cycle producing 36 molecules of ATP by every 
two molecules of pyruvate [176]. To avoid confusion while reading this topic, it would 
be easier to digest all these pathways by showing a simple diagram with all metabolic 
pathways together, before getting into the full glycolytic pathway and the Krebs cycle 
(Figure 6). 
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Figure 6 – Glycolysis and the Krebs cycle 
The production of energy in most mammalian cells starts through the glycolytic 
pathway converting glucose into two molecules of pyruvate, producing 2 ATPs. 
Pyruvate is converted into Acetyl CoA within the mitochondrial space and enters the 
Krebs cycle in the form of citrate producing 36 ATPs.  
 
Glycolysis is the process of breaking down glucose to convert it into pyruvate, 
and this reaction does not require oxygen directly. In glycolysis, glucose is transported 
inside the cell, and it is converted into glucose-6-phosphate, which thenis committed 
to undergo glycolysis resulting into the production of two molecules of pyruvate and 
ATP for every molecule of glucose [176]. Glycolysis can be carried out under 
anaerobic conditions until the point of pyruvate conversion. Under anaerobic 
conditions, pyruvate is transformed to lactate by lactate dehydrogenase producing 
ATP from the glycolytic pathway and replenishing the system quickly, although to the 
cost of producing lactic acid [176]. On the other hand, when O2 is present pyruvate is 
transported to the mitochondria converted to acetyl-CoA and entered into the citric 
acid cycle, also known as the Krebs cycle [177]. It is essential to mention that the 
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opposite reaction, the conversion of non-carbohydrates substrates to glucose, can 
also be carried out by mammalian cells in a process known as gluconeogenesis [178]. 
Gluconeogenesis is an important mechanism to store energy and maintain normal 
blood glucose levels when required, and this process mainly takes place within liver 
cells [178]. Some enzymes within the glycolytic pathway will be discussed later; 
therefore, the full pathway can be reviewed in Figure 7. 
 
Figure 7 – Glycolytic pathway 
The diagram shows the main glycolytic pathway with intermediates and enzymes. The 
red arrows indicate an irreversible reaction, in most of the cells, while the blue arrows 
indicate steps involved in gluconeogenesis. Image adapted from, Human biochemistry 
chapter 8, figure 8.5 [178].  
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 While the Krebs cycle is the process of converting acetyl-CoA into ATP through 
a series of biochemical reactions, it is not the Krebs cycle which produces the ATP, 
but the electron transport chain (ETC). During the Krebs cycle, a molecule known as 
nicotinamide adenine dinucleotide (NAD+) is converted to its reduced form, NADH. 
The ETC oxidises NADH by a series of mitochondrial transmembrane protein 
complexes producing NAD+ within the inner of the mitochondria and transferring 
protons (H+) to the intermembrane mitochondrial space [176]. This process creates an 
electrochemical H+ gradient that favours the synthesis of ATP, from ADP, by a proton 
pump under the name of ATP synthase. In summary, one molecule of glucose is 
converted into two pyruvates within the cell. Moreover, under aerobic conditions 
pyruvate is converted to acetyl-CoA entering the Krebs cycle producing NADH, and 
also FADH, which is oxidised by the ETC producing ATP from the electrochemical 
gradient generated by this process [177]. An overview of the full Krebs cycle can be 
reviewed in Figure 8 and a simplification of the ETC in Figure 9. 
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Figure 8 – The Krebs cycle 
The diagram shows the Krebs cycle, citric acid cycle, with all the intermediates and 
enzymes. During the Krebs cycle citrate is converted to oxaloacetate by a series of 
enzymatic reactions and H2O, CO2 and NADH/FADH2 are produced. This process is 
carried out inside the mitochondrial space. Image adapted from Narayanese, 
WikiUserPedia, YassineMrabet, TotoBaggins -http://biocyc.org/META/NEW-
IMAGE?type=PATHWAY&object=TCA 
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Figure 9 – Electron transport chain 
The ETC is the process of converting NADH/FADH2 into ATP by mitochondrial 
complexes I, II, II and IV. During these processes, a proton gradient is produced in 
mitochondrial intermembrane space creating the conditions for ATP production by the 
ATP synthase pump. Oxygen is the final electron acceptor in the ETC, and without it, 
the ETC and Krebs cycle stop favouring glycolysis. Image source: Fvasconcellos 
22:35, 9 September 2007 (UTC) - Vector version of w:Image:Etc4.png by Tim Vickers, 
content unchanged., Public Domain. 
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Finally, it is important to mention that under certain circumstances, the cells 
favour the glycolytic pathway and lactic acid formation even under aerobic conditions. 
This phenomenon was first described in cancer cells by Otto Heinrich Warburg, and 
he referred to this process as the Warburg effect [179]. Interestingly, specific immune 
cells, when activated, display a similar metabolic behaviour like the one seen in cancer 
cells, favouring the quick production of ATP via glycolysis and lactic acid formation, 
which is going to be discussed in the next section [180-182]. Indeed, genetic mutations 
that affect critical proteins of these metabolic pathways can generate metabolic 
disorders which are known to have an impact on human health.            
 
1.4.2 Immunometabolism: macrophage metabolism 
Immunometabolism has been a hot topic in the field of immunology over the past 
decade. While this topic was undoubtedly introduced more than 40 years ago, today 
new technological advances allow us to explore this field with better detail [183]. One 
of the first articles published in macrophage metabolism was in 1986, describing the 
high enzymatic activity of hexokinase during glycolysis, but a low glucose utilisation 
on resting or non-activated macrophages [184]. Later it was found that macrophages 
have a rapid glucose consumption via the glucose transporter 1 (GLUT1) when 
stimulated with LPS, contributing to the systemic hypoglycemia seen during 
endotoxemia [185]. Glycolysis is indeed the pathway of preference of activated M1 
macrophages and T cells, providing these cells with a rapid energy source needed for 
the circumstances encountered [183]. While glycolysis is crucial in the activation of 
the pro-inflammatory M1 macrophages, it is not the same for their counterpart anti-
inflammatory M2 macrophages. Activated M2 macrophages prefer the production of 
ATP through the Krebs cycle and oxidative phosphorylation [186]. Usually, during the 
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resolution of the inflammatory response the normal oxygen levels are restored within 
the tissue and cytokines, such as IL-4 and IL-13, are secreted favouring oxidative 
phosphorylation and the polarisation of M2 macrophages [187, 188]. In the case of M1 
macrophages hypoxia, bacterial components, PAMPs, DAMPs, ROS and other 
danger signals, induce macrophage activation upregulating glycolysis promoting the 
inflammatory response [187, 188]. It has been shown that during hypoxia, the 
transcription factor HIF1, alongside with succinate, is upregulated in macrophages 
favouring the production of IL-1 [189, 190]. In a different study, it was shown that 
accumulation of ROS within macrophages induce the transcription of TXNIP favouring 
the production of IL-1 [191]. Interestingly, when the hexokinase inhibitor 2-
deoxyglucose (2-DG) was administered to macrophages, before activation, the 
inflammatory response was significantly reduced [192-194]. 2-DG certainly reduces 
the inflammatory response; however, it was recently shown that 2-DG treatment 
decreases the amount of M2 macrophage polarisation, inhibiting the expression of 
some of the most common markers of M2 polarisation, such as Arg, Ym-1, and CD206 
[195]. Heightened glycolysis has also been shown in LPS-activated dendritic cells 
(DC), activated NK, effector T and B cells [183]. Macrophages which are activated via 
LPS/IFN, TLR-2, TLR-3, TLR-4 and TLR-9 showed higher activity of ubiquitous 
phosphofructokinase-2 (uPFK2), rather than the liver-PFK2, increasing the glycolytic 
flux [196]. The first enzyme in the glycolytic pathway, hexokinase 1, is a critical 
regulator of the NLRP3 inflammasome, interacting with the NLRP3 complex within the 
mitochondrial space, resulting in its activation and realising IL-1 [197]. 
  While glycolysis is indeed an essential player in the inflammatory response the 
Krebs cycle and the ETC are also crucial players in immune cell activation. For 
instance, in memory T cells, the pathway of preference is the Krebs cycle and the 
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ETC, this is mainly due to their quiescent activity [198]. The Krebs cycle is a central 
regulator of macrophage polarisation and behaviour. While in M2 macrophages there 
is a fully functional Krebs cycle followed by the production of ATP by the ETC, in M1 
macrophages there is a disruption of the citric acid cycle with the accumulation of 
citrate and succinate (Figure 10) [186]. The accumulation of citrate favours the fatty 
acid synthesis pathway, allowing these phagocytic cells to be able to engulf bacterial 
pathogens with the formation of cellular membrane [183]. Citrate accumulation also 
induces the production of itaconate a potent newly described antimicrobial and anti-
inflammatory metabolite, alongside the formation of nitric oxide (Figure 10) [199-201]. 
The other part of the Krebs cycle that is disrupted is the conversion of succinate to 
fumarate. In fact, it has been suggested that itaconate prevents succinate 
dehydrogenase from regulating succinate and IL-1 production (Figure 10) [201]. 
Another study demonstrated that itaconate mainly induces its potent anti-inflammatory 
effects via NRF2 activation and further inhibition of IL-1 [199]. Certainly, itaconate is 
a potent anti-inflammatory metabolite; however, its mechanism of action remains to 
be fully deciphered. Immune cells differ widely and require unique types of metabolism 
depending on their function. It is crucial to understand how these metabolic pathways 
are affected at the molecular level during disease and what are the consequences of 
these disruptions, not only in macrophages but in other immune cells as well. 
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Figure 10 – The Krebs cycle in M1 and M2 macrophages 
M2 macrophages display a fully functional Krebs cycle with the efficient production of 
ATP. When activated, with LPS/IFN, M1 macrophages undergo metabolic 
reprogramming favouring glycolysis and breaking the Krebs cycle. Citrate and 
succinate are accumulated having as a bio-products, respectively itaconate and IL-1. 
Reprinted by permission from Springer Nature: (Nature Reviews Immunology) [183] 
Copyright Clearance Centre RightsLink® 2019.  
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1.5 Hypotheses 
 
1.5.1 List of Hypotheses 
Hypothesis 1: Atypical activation of the UPR, existing in HBECs, is CFTR 
genotype-dependent.  
Hypothesis 2: Activation of the UPR is only present in specific subsets of 
immune cells. 
Hypothesis 3: Cells with CFTR mutations present an abnormal metabolic state 
associated with UPR activation. 
Hypothesis 4: That the abnormal metabolic state and UPR activation seen in 
CF is related to the exaggerated inflammatory responses. 
 
1.5.2 Aims and Objectives 
Hypothesis 1: 
1 – To establish whether UPR activation is different in HBECs bearing various 
CFTR mutations.  
2 – To investigate whether this UPR activation leads to an exaggerated 
inflammatory response in different HBECs with various CFTR mutations. 
3 – To investigate whether CF HBECs respond similarly after stimulations with 
bacterial components and UPR inducers. 
Hypothesis 2:  
1 – To investigate whether the UPR activation is specific for individual immune 
cells or all CFTR mutated cells are affected by ER stress. 
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2 – To investigate whether the exaggerated inflammatory response seen in CF 
immune cells is UPR dependent. 
3 – To investigate how immune cells affected by ER stress respond to 
stimulations with bacterial components and ER stressors. 
Hypothesis 3:  
1 – To investigate whether the innate immune cells affected by ER stress 
display an abnormal metabolic state. 
2 – To investigate the mitochondrial function and glycolytic flux of monocytes 
and M1 macrophages bearing CFTR mutations  
3 – To investigate whether this abnormal hypermetabolic state is associated 
with the UPR activation seen in CF cells.   
Hypothesis 4: 
1 – To establish whether the abnormal metabolic state and the UPR activation 
seen in CF macrophages are associated with the exaggerated inflammation  
2 – Investigate the impact of IRE1 in the abnormal metabolic state seen in CF 
macrophages. 
3 – To investigate how CF small molecule therapies impact in macrophage 
metabolism.  
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Chapter 2 – Methods 
2.1 Cellular culture 
 
2.1.1 Cell Lines 
A full table of resources is provided at the end of this chapter with all the details 
of the chemicals, reagents, cell lines and software used during this research Table 5. 
Four different HBEC lines were used during this research. The control cell line BEAS2-
BWT/WT and three CF cell lines with different CFTR mutations, CuFi-1F508/F508, CuFi-
4G551D/F508 and IB3-1F508/W1282X were obtained from ATCC, all the details regarding 
these cell lines are deposited in their web page. HBEC lines were grown on Cell+ 
surface plates or flasks (Sarstedt) under sterile conditions in a category two tissue 
culture hood. BEAS-2B and IB3-1 cells were cultured in LHC basal medium (Thermo 
Fisher Scientific) supplemented with 10% FBS, 50 U/ml penicillin and 50 μg/ml 
streptomycin (1%P/S).  CuFi-1 and CuFi-4 were cultured in LHC-9 medium (Thermo 
Fisher Scientific), as described by the manufacturer. Cell lines were expanded initially 
in T75, and T175 positively charged flasks (Sarstedt) in an incubator at 37°C and 5% 
CO2, 95% air atmosphere. Cells were left to grow until 80-90% confluency was 
reached, and then washed once with Dulbecco's phosphate-buffered saline (DPBS) 
without calcium and magnesium (Gibco). After washing, cells were detached using 1X 
(0.05%) Trypsin-EDTA (Thermo Fisher Scientific) for no longer than 15 min in the 
incubator. After the cells where detached, trypsin was neutralised with the 
corresponding media and cells were centrifuged at 300 g for 5 min. After 
centrifugation, the supernatant was carefully removed to avoid disturbing the cell 
pellet, and cells were resuspended in the corresponding media. Cells were counted 
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and seeded into six-well positively charged plates (Sarstedt) at 1x106 cells per well in 
1ml of media and left overnight to allow cells to adhere to the plate. 
 
2.1.2 Isolation and processing of primary immune cells 
All work involving human samples from patients with CF or HC volunteers was 
approved by the Health Research Authority, research ethics committee reference 
17/YH/0084. Patients diagnosed with CF were recruited from the adult cystic fibrosis 
unit at St. James’s University Hospital, Leeds. All patients had disease-causing CFTR 
mutations and clinical features consistent with the diagnosis of CF. Patients who were 
post-lung transplant, suffering from clinical exacerbations, on CFTR modulators or 
clinically not stable were excluded from this study unless otherwise stated. Informed 
written consent was obtained from all participants at the time of the sample collection. 
Age and sex-matched healthy controls were recruited from the St. James's University 
Hospital premises, Leeds, UK. 
 
CF (n = 62) HC (n = 37) 
Age range (years) 19-50 (32) 21-44 (29) 
Male (%) 54.84% 48.65% 
CFTR genotype  
F508 / F508 88.71% N/A 
F508 / 621+1 (G>T) 1.61% N/A 
F508 / G551D 1.61% N/A 
W1282X / W1282X 1.61% N/A 
F508del / c.1521_1523delCTT 4.84% N/A 
3484C>T (p.Arg1162X) / R1162X  1.61% N/A 
BMI (mean) 23.1 N/A 
FEV1 (%) 45.9% N/A 
Table 2 – Patients’ information and clinical data. 
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Blood samples were collected in EDTA pre-coated tubes (Greiner-bio-one) and 
processed the same day of collection. PBMCs were isolated from whole blood using 
a standard density gradient centrifugation method. Blood was mixed with an equal 
volume of DPBS without Ca2+ and Mg2+ containing 2% FBS, referred from now on as 
DPBS separation buffer, and mixed by pipetting up and down. Then 37ml of the 
homogenous mixture was carefully layered onto 15ml of Lymphoprep (Stem Cell) and 
centrifuged at 1200g for 20 min at full speed and without brakes. The white buffy layer 
was carefully removed and washed twice in DPBS separation buffer by centrifuging, 
the first time at 300g for 5 min full speed with full brake, and the second time 180g for 
10 min full speed without breaks, to remove platelets. Finally, PBMCs were counted 
and resuspended in RPMI medium (Merck) containing 10% FBS, 2 mM L-glutamine, 
50 U/mL penicillin and 50 μg/mL streptomycin, referred from now on as complete 
RPMI medium. 
Isolation of specific subsets of immune cells was done as follows. Isolation of 
human lymphocytes was carried out directly from blood using the EasySep Direct 
Human Total Lymphocyte Isolation Kit (Stem Cell) following the manufacturer’s 
instructions. Primary neutrophils were isolated directly from blood using the EasySep 
Direct Human Neutrophil Isolation Kit (Stem Cell) following the manufacturer’s 
instructions. Monocytes were isolated the same day after collection of the PBMCs 
using the Pan Monocyte Isolation Kit, human (Miltenyi Biotec), following all the 
manufacturer’s instructions. All cells were cultured in complete RPMI medium (Merck) 
and kept in a humidified incubator at 37°C, 5% CO2. 
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2.1.3 Culture of primary immune cells 
After isolation, described in the previous section, PBMCs, lymphocytes, 
neutrophils, monocytes and macrophages were cultured in complete RPMI medium 
(Merck). PBMCs and lymphocytes were seeded at 2×106 cell/ml, plated in 6 well plates 
and stimulated the day after. Neutrophils were seeded at 3×106 cell/ml, plated in 6 well 
plates and stimulated the same day. Monocytes were seeded at 1×106 cell/ml, plated 
in 6 well plates and stimulated the next day. All cells were cultured in complete RPMI 
medium (Merck) and kept in a humidified incubator at 37°C, 5% CO2. 
 
2.1.4 Macrophage culture and polarisation 
After monocytes were counted and plated as described before, the next protocol 
for macrophage differentiation and polarisation was performed. Initially, monocytes 
were cultured in complete RPMI medium (Merck) supplemented with either 20 ng/mL 
human GM-CSF (Pepro Tech), for M1 differentiation, or 20 ng/mL human M-CSF 
(Pepro Tech), for M2 differentiation. Monocytes were incubated for six days adding 
half of the initial media, without removing the initial media, with their respective factors 
on day 3. On day six M0 macrophages were activated with either 100 ng/mL human 
IFN- (Pepro Tech) and 50 ng/mL LPS, for M1 macrophage polarisation, or 20 ng/mL 
IL-13 (Pepro Tech) and 20 ng/mL IL-4 (Pepro Tech), for M2 macrophage polarisation, 
and incubated for further 24 h. 
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2.2 RNA Isolation and detection 
 
2.2.1 RNA isolation and cDNA conversion 
Total RNA isolation was performed using TRIzol reagent and the Phasemaker 
Tubes (Thermo Fisher Scientific) according to the manufacturer's protocol. Briefly, 
after stimulation and removal of the supernatants, 1 ml of TRIzol reagent was added 
to the cells, and the mixture was homogenised by pipetting up and down several times. 
Samples were stored at -80°C until extraction. RNA extraction was performed 
following the manufacturer’s instructions incorporating the Phasemaker Tubes 
(Thermo Fisher Scientific) to avoid DNA contamination. After the extraction, the RNA 
quality and quantity were further determined by 260/280 and 260/230 ratios using a 
NanoDrop spectrophotometer, and only samples with 260/280 ratios above 1.75 and 
260/230 ratios above 1.90 were used. RNA was converted to cDNA using no more 
than 1 mg of the sample with the High-Capacity cDNA Reverse Transcription Kit 
(Thermo Fisher Scientific). cDNA was stored at -20°C until used to run qPCR. 
 
2.2.2 Real-time PCR (qPCR) 
Gene expression was quantified by qPCR in the QuantStudio 7 Flex Real-Time 
PCR System (Applied Biosystems) using Power SYBR Green PCR Master Mix 
(Thermo Fisher Scientific) or TaqMan Universal PCR Master Mix (Thermo Fisher 
Scientific) in 384 well plates done in triplicates or duplicates. Custom-synthesized 
oligonucleotide primers (Integrated DNA Technologies), designed with the online 
Primer-Blast designing tool or pre-designed TaqMan oligonucleotide primers , were 
used to quantify mRNA. All designed primers were used at concentrations of 300nM. 
Sequences used can be found in Table 3.  Relative mRNA expression was calculated 
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using the Ct method with HPRT and PPIA as the housekeeping genes to normalise 
other mRNAs. A total of 15ng of cDNA was used in each reaction. All primer 
sequences showed specific amplification of only one product, based on melt curves, 
and no primer-dimer amplification. All values used were between 10 to 33 cycles. 
Gene 
Target 
Forward  
Sequence (5'->3') 
Reverse 
Sequence (5'->3') 
BiP GAACGTCTGATTGGCGATGC TCAACCACCTTGAACGGCAA 
IRE1 TAGTCAGTTCTGCGTCCGCT TTCCAAAAATCCCGAGGCCG  
PERK GCGCGGAAAGTTTGCTCAAT GAGCTCCCAAGAAGGCAAGG 
ATF6 ATGAAGTTGTGTCAGAGAACC CTCTTTAGCAGAAAATCCTAG 
XBP1s CTGAGTCCGCAGCAGGTG AGTTGTCCAGAATGCCCAACA 
XBP1u TCCGCAGCACTCAGACTACG AGTTGTCCAGAATGCCCAACA 
ERdj4 GTCGGAGGGTGCAGGATATTAG  GCGCTCTGATGCCGATTTTG  
CHOP GGAACCTGAGGAGAGAGTGTT GTCCCGAAGGAGAAAGGCAA 
GADD34 CTGGCTGGTGGAAGCAGTAA TATGGGGGATTGCCAGAGGA 
ATF4 GCCAAGGGGGAAGCGATTTA  CTACGCTTTCCCGATCCCAG  
IL-6 CCAGCTATGAACTCCTTCTC GCTTGTTCCTCACATCTCTC 
TNF CACCACTTCGAAACCTGGGA TGTAGGCCCCAGTGAGTTCT 
HPRT GGAAAGAATGTCTTGATTGTGGAAG GGATTATACTGCCTGACCAAGGAA 
PPIA ACGTGGTATAAAAGGGGCGG CTGCAAACAGCTCAAAGGAGAC 
PDK4 Assay ID: Hs01037712_m1 
PFKB1 Assay ID: Hs00997227_m1 
HK2 Assay ID: Hs00606086_m1 
ESRRA Assay ID: Hs00607062_gH 
PPARA Assay ID: Hs00947536_m1 
UCP3 Assay ID: Hs01106052_m1 
HPRT Assay ID: Hs02800695_m1 
Table 3 – Primer sequences 
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2.2.3 Reverse transcription PCR (RT-PCR) 
XBP1 mRNA splicing was also detected by reverse transcription (RT)-PCR using 
the following set of primers: Forward 5′-CTGAAGAGGAGGCGGAAGC-3′ and reverse 
5′-AATACCGCCAGAATCCATGG-3′, which recognise both the XBP1s and XBP1u 
mRNA. The reaction was performed using the OneTaq Hot Start DNA Polymerase kit 
(New England Biolabs) using the Routine PCR protocol described by the 
manufacturer. The PCR thermal cycling profile was: 1cycle at 94°C for 5 min, 35 cycles 
at 94°C for 30s/55°C for 30s/72°C for 1min, one cycle at 72°C for 10 min. The 
transcripts were then identified on a 3.5% agarose gel using ultra-pure agarose and 
TBS buffer, and visualised against a 100bp ladder on the BioRad Gel Doc.  Gels were 
run at 120V for 1-2 hours. 
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2.3 Cytokine expression 
 
Cytokines levels from cell cultured media were detected by the IL-6, TNF, and IL-
10 ELISAs kits listed in the table of reagents, following the manufacturer’s 
recommendations.  Supernatants were collected from stimulated cells and stored at -
80°C until required. Briefly, ELISA plates were coated with 100 μl cytokine capture 
antibody in PBS overnight at 4°C. Plates were washed four times with PBST (PBS 
containing 0.5% Tween 20) and the wells blocked in 300 μl assay buffer (0.5% BSA, 
0.1% Tween 20 in PBS) by incubating for one h. Then, plates were washed twice with 
PBST and 100 μl of sera/culture supernatants, together with appropriate standards, 
were added to wells in duplicates. 50 μl of detection antibody was added to all wells 
and incubated for two h. After incubation, the plates were washed five times with PBST 
and 100 μl of tetramethybenzidine (TMB) substrate solution (Sigma) was added to all 
wells and incubated for 30 min. The reaction was stopped by adding 100 μl of 1.8 N 
H2SO4 and absorbance measured at 450 nm and reference at 620 nm. All incubation 
steps were done at room temperature with continual shaking at 700 rpm. 
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2.4 Western blots  
 
After stimulation cells were washed with DPBS and then lysed using 
radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris-Cl, 1 mM EDTA, 1% Triton 
X-100, 0.1% sodium deoxycholate, 0.1% SDS and 140 mM NaCl), containing 10% 
(w/v) protease and phosphatase inhibitor cocktail (Roche and Sigma). The samples 
were then homogenised by pipetting up and down several times and stored at -80°C. 
Then, samples were centrifuged at 14,000 g for 10 min and the supernatant 
transferred to another Eppendorf tube for further quantification using bicinchoninic 
acid assay (BCA). Proteins were resolved by SDS-PAGE using 10% polyacrylamide 
gels at 100 V for 1 hour and transferred to immobilon polyvinylidene difluoride (PVDF) 
membrane (Bio-Rad) for 1 hour. Following electrotransfer in transfer buffer (25 mM 
Tris, 192 mM glycine, and pH 8.3, 20% methanol) at 100 V for one h, the membranes 
were blocked for one h in blocking solution (PBS containing 0.1% Tween 20 and 5% 
(w/v) non-fat milk). After four washes in PBST (PBS with 0.5% Tween 20), primary 
antibodies were incubated with PVDF membrane overnight at 4°C. The membrane 
was washed three times with PBST, and secondary antibody HRP-linked antibody was 
added and incubated for one h with constant rocking at room temperature. The 
membrane was washed five times with PBST and 3 ml of ECL detection system 
(Merck) were added to the membrane for 1 min, before being imaged with the 
ChemiDoc Imaging System (Bio-Rad). 
 
 
2.5 Flow cytometry 
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The CytoFLEX-S (Beckman Coulter) was used for the detection of (PE) IRE1, 
(PerCP) pIRE1, (AF647) ATF6 and (AF488) PERK in the HBEC lines. For the 
characterisation of M1/M2 macrophages the surface and intracellular markers, 
referenced in the Inflammation and the UPR in Cystic Fibrosis section, were used and 
analysed in the BD Bioscience FACS Calibur. Compensation was done by 
fluorescence minus one (FMO) for all the antibodies and using the isotype controls to 
identify non-specific binding. During sample acquisition, 20,000-30,000 events were 
captured per sample, consistent with each experiment. The pIRE1 (GeneTex) and 
its Rabbit IgG isotype control (GeneTex) antibodies were conjugated using the LYNX 
Rapid PerCP Antibody Conjugation Kit (Bio-Rad), as per the manufacture's 
recommendations.  Brilliant stain buffer (BSB) was used as the final resuspension 
buffer for running the samples. Human IgG (Merck I2511) and Mouse serum (M5905) 
were used to ‘Fc Block’ the cells when mentioned. 
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2.6 Immunofluorescence microscopy 
 
Cells were visualised by Immunofluorescence (IF) using the CFTR monoclonal 
antibody (Cell Signaling) and an isotype control. The next protocol was followed: 
monocytes were differentiated into M1, or M2 macrophages in eight well millicel EZ 
microscope slides (Merck), following the protocol described before. Cells were fixed 
for 20 min in 4% paraformaldehyde at room temperature, washed 3X with PBS and, 
when indicated, permeabilised for 15 min either with 0.2% Triton X-100 solution or 
Saponin in PBS (3% BSA). Cells were washed 3X with PBS, then the primary antibody 
was added (CFTR 1:800) or the isotype control (1:800) and incubated overnight at 
4°C. Cells then were washed 3X with PBS and incubated for two h at room 
temperature with the secondary antibody (Anti-rabbit IgG CS 1:1000). To stain the 
actin filaments phalloidin dye (Insight Biotechnology) was included with the secondary 
antibody at final concertation of 40 U/ml. Cells were washed 3X with PBS, and a drop 
of ProLong diamond anti-fade with DAPI (Thermo Fisher) was added to each slide and 
covered. The slides were left for 24 h at room temperature in the dark. Cells were 
visualised using the confocal laser scanning microscope - Nikon A1R and all images 
were taken using the same parameters during sample acquisition. Excitation lasers 
used 405nm, 457-514nm, 561nm and 642nm. Fluorescent emission was captured at 
the wavelength recommended by the manufacturer of each antibody.   Images were 
produced using the Nikon NIS Elements Analysis software. Images were acquired on 
a Leica TCS SP confocal microscope with a 
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2.7 Metabolic experiments 
 
2.7.1 Cellular ROS detection 
ROS were measured by using the Cellular ROS Assay Kit (Abcam) as 
described by the manufacturer. Fluorescence was detected with excitation at 485 nm 
and emission at 535 nm using the Cytation 5 Imaging Plate Reader (BioTek).  
 
2.7.2 Glycolytic and mitochondrial assays (Extracellular Flux Analyzer) 
All the metabolic parameters were calculated as shown in Table 4. Normally 3–
5 technical replicates per sample were examined. Immediately after the metabolic 
analysis, cells were fixed for 10 min in methanol/acetone (4:1), and cell number of 
each well was determined by nuclear DNA staining with DAPI (BD Biosciences), 
ECAR and OCR values were normalised accordingly. 
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Parameter Equation 
Glycolysis (maximum rate measurement after glucose 
stimulation) – (rate measurement before 
glucose stimulation) 
Glycolytic capacity (maximum rate measurement after glucose 
stimulation) – (maximum rate 
measurement after oligomycin stimulation) 
Glycolytic reserve (maximum rate measurement after 
oligomycin stimulation) – (rate 
measurement before oligomycin 
stimulation) 
Basal respiration (measurement before oligomycin 
stimulation) – (rate measurement after 
rotenone/antimycin A stimulation) 
Proton leak (minimum rate measurement after 
oligomycin stimulation) – (minimum 
measurement after rotenone/antimycin A 
stimulation) 
Maximal respiration (maximum rate measurement after FCCP 
stimulation)– (minimum rate measurement 
after rotenone/antimycin A stimulation) 
Reserve respiratory capacity (maximal respiration) – (basal respiration) 
ATP production (basal respiration) – (minimum rate 
measurement after oligomycin stimulation) 
Table 4 – Seahorse Calculations 
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2.8 Statistical analysis 
 
No statistical tests were used to predetermine sample size. All statistical analyses 
were performed using GraphPad Prism v7. Data are presented as mean ± SEM. P-
values of P < 0.05 were considered to be statistically significant. Statistical significance 
was determined using Two-way ANOVA, Dunnett's test with Bonferroni-Dunn 
correction when comparing between different cell lines. Paired Student's t-test was 
used when comparing drug responses within the same cell line, *p < 0.05, **p < 0.01, 
***p < 0.001. Statistical comparisons were performed by unpaired independent 
Student's t-test, *p < 0.05, **p < 0.01, ***p < 0.001 when comparing between groups. 
Mann-Whitney non-parametric test was used to compare the medians between 
groups, *p < 0.05, **p < 0.01, ***p < 0.001. 
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2.9 Table of resources 
 
REAGENT or RESOURCES SOURCE IDENTIFIER 
Antibodies 
IRE1 alpha (phospho Ser724) GeneTex  Cat# GTX63722; RRID: N/A 
Rabbit IgG isotype control GeneTex Cat# GTX35035; RRID: N/A 
IRE1α Antibody (B-12) PE Santa Cruz Cat# sc-390960-PE; RRID: N/A 
Normal mouse IgG1 PE (Isotype) Santa Cruz Cat# sc-2866; RRID: AB_737219 
ATF-6α Antibody (F-7) AF647 Santa Cruz Cat# sc-166659- AF488; RRID: 
AB_2058901 
Normal mouse IgG1 Alexa Fluor 647 Santa Cruz Cat# sc-24636; RRID: AB_737215 
PERK Antibody (B-5) AF488 Santa Cruz Cat# sc-377400; 
RRID:AB_2762850 
Normal mouse IgG1 Alexa Fluor 488 Santa Cruz Cat# sc-3890; RRID: AB_737214 
V500 Mouse Anti-Human CD14 BD Biosciences Cat# 561391; RRID: AB_10611856 
Anti-HLA-DR PerCP BD Biosciences Cat# 347402; RRID: N/A 
FITC Mouse Anti-Human CD206 BD Biosciences Cat# 551135; RRID: AB_394065 
PE Rat Anti-Human IL-10 BD Biosciences Cat# ; RRID: AB_397227 
APC Mouse Anti-Human CD274 BD Biosciences Cat# 563741; RRID: AB_2738399 
PE-Cy7 Mouse Anti-Human CD86 BD Biosciences Cat# 561128; RRID: AB_10563077 
BV421 Mouse Anti-Human TNF BD Biosciences Cat# 562783; RRID: AB_2737790 
Purified anti-XBP-1s Antibody BioLegend Cat# 619501; RRID: AB_315907 
HPRT Antibody (FL-218) Santa Cruz Cat# sc-20975; RRID: N/A 
Goat anti-Rabbit IgG (H+L) Poly-HRP 
Secondary Antibody 
Thermo Fisher 
Scientific 
Cat# 32260; RRID: AB_1965959 
CFTR (D6W6L) Rabbit mAb Cell Signaling 
Technology 
Cat# 78335; RRID:AB_2799913 
Anti-rabbit IgG (H+L), F(ab')2 Fragment 
(Alexa Fluor 488 Conjugate) 
Cell Signaling 
Technology 
Cat# 4412; RRID:AB_1904025 
Biological Samples 
Human Blood Samples St James's University 
Hospital 
Health Research Authority REC 
reference 17/YH/0084 
Chemicals, Peptides, and Recombinant Proteins 
Lymphoprep StemCell 
Technologies 
Cat# 07861 
EasySep Direct Human Total Lymphocyte 
Isolation Kit 
StemCell 
Technologies 
Cat# 19655 
EasySep Direct Human Neutrophil 
Isolation Kit 
StemCell 
Technologies 
Cat# 19666 
Pan Monocyte Isolation Kit, human Miltenyi Biotec Cat# 130-096-537 
Recombinant Human GM-CSF Pepro Tech Cat# 300-03 
Recombinant Human M-CSF Pepro Tech Cat# 300-25 
Recombinant Human IFN-γ Pepro Tech Cat# 300-02 
Recombinant Human IL-13 Pepro Tech Cat# 200-13 
Recombinant Human IL-4 Pepro Tech Cat# 200-04 
LPS InvivoGen Cat# tlrl-3pelps 
48c Merck Cat# 412512 
MKC-3946 Cayman Chemical Cat# 19152 
PowerUp SYBR Green Master Mix Thermo Fisher 
Scientific 
Cat# A25780 
TaqMan Universal PCR Master Mix Thermo Fisher 
Scientific 
Cat# 4304437 
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TRIzol Reagent and Phasemaker Tubes 
Complete System 
Thermo Fisher 
Scientific 
Cat# A33251 
Thapsigargin Merck Cat# T9033 
Tunicamycin Cell Signaling 
Technologies 
Cat# 12819S 
PhosSTOP Merck Cat# 4906845001 
Pierce Protease Inhibitor Mini Tablets Thermo Fisher 
Scientific 
Cat# A32955 
Immobilon Western Chemiluminescent 
HRP Substrate 
Merck Cat# WBKLS0500 
DPBS, no calcium, no magnesium Thermo Fisher 
Scientific 
Cat# 14190144 
Trypsin-EDTA (0.5%), no phenol red Thermo Fisher 
Scientific 
Cat# 15400054 
StemPro Accutase Cell Dissociation 
Reagent 
Thermo Fisher 
Scientific 
Cat# A1110501 
ProLong Diamond Antifade Mountant with 
DAPI 
Thermo Fisher 
Scientific 
Cat# P36966 
Phalloidin, CF555, 50u Insight Biotechnology Cat# 00040-T 
Critical Commercial Assays 
High-Capacity cDNA Reverse 
Transcription Kit 
Thermo Fisher 
Scientific 
Cat# 4368814 
ELISA IL-6 Human Thermo Fisher 
Scientific 
Cat# CHC1263 
ELISA TNF alpha Human Thermo Fisher 
Scientific 
Cat# CHC1753 
ELISA IL-10 Human Thermo Fisher 
Scientific 
Cat# CHC1323 
LYNX Rapid PerCP Antibody Conjugation 
Kit 
Bio-Rad Cat# LNK072PERCP 
Fixation/Permeabilization Solution Kit BD Biosciences Cat# 554714 
Glycolysis Stress Test Kit Agilent Technologies Cat# 103020-100 
Pierce BCA Protein Assay Kit Thermo Fisher 
Scientific 
Cat# 23225 
VACUETTE EDTA pre-coated tubes Greiner-bio-one Cat# 455036 
OneTaq Hot Start DNA Polymerase New England Biolabs Cat# M0481 
UltraPure Agarose Thermo Fisher 
Scientific 
Cat# 16500100 
DCFDA / H2DCFDA - Cellular ROS 
Assay Kit 
Abcam Cat# ab113851 
MitoSOX Red Mitochondrial Superoxide 
Indicator, for live-cell imaging 
Thermo Fisher 
Scientific 
Cat# M36008 
Dead Cell Apoptosis Kit with Annexin V 
Alexa Fluor(tm) 488 & Propidium Iodide 
(PI) 
Thermo Fisher 
Scientific 
Cat# 10652071 
Experimental Models: Cell Lines 
BEAS-2B cell line ATCC ATCC CRL-9609 
CuFi-1 cell line ATCC ATCC CRL-4013 
CuFi-4 cell line ATCC ATCC CRL-4015 
IB3-1 cell line ATCC ATCC CRL-2777 
Oligonucleotides 
Primer Sequences See Table 3 Integrated DNA 
Technologies 
N/A 
Software and Algorithms 
GraphPad Prism7 Graphpad software N/A 
CytExpert Software Beckman Coulter N/A 
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Flow Jo Vx0.7 FlowJo, LLC N/A 
Agilent Seahorse Wave Agilent Technologies N/A 
Table 5 – Table of resources 
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Chapter 3 – The UPR in Cystic Fibrosis 
3.1 Introduction 
 
The UPR plays a vital role in the regulation of cellular homeostasis. CFTR 
abnormalities, present in patients with CF, disrupt the cellular balance by favouring 
inflammation [113, 172]. While atypical activation of the UPR in CF has already been 
shown [172], this current study was done to compare the IB3-1F508/W1282X and C38 
(IB3-1 transfected with CFTR by an adeno-associated viral vector) cell lines [172]. The 
C38 cell line represents the corrected version of the CF IB3-1 cells; however, the C38 
cells still produce the mutated F508 CFTR, with potential implications in cellular 
stress and UPR activation [172]. For this reason, it is essential to examine UPR 
activation using a range of other CF HBECs with different type class mutations. 
Furthermore, it is of great interest to explore whether the type of class mutation present 
in CF HBECs may be associated with different degrees of UPR activation. Certainly, 
UPR activation exists in alveolar macrophages from patients with CF; however, this 
finding has never been shown in other immune cells [113]. Although one study has 
demonstrated XBP1s upregulation in PBMCs from patients with CF, this UPR 
activation might be due to proportional differences in immune cells, as PBMCs are a 
mixed population of different immune cells [172]. Based on this, we wanted to expand 
this finding by isolating different subsets of immune cells, to fully explore UPR 
activation in individual clusters of immune cells. Furthermore, alveolar macrophages, 
also known as tissue-resident macrophages, have a different origin from monocyte-
derived macrophages, as the latter are originated from the bone marrow [188]. We 
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also wanted to explore whether this XBP1s irregularity was still present in different 
subsets of macrophages. 
3.2 Methods 
 
3.2.1 RNA isolation and detection 
The following cell numbers were used for RNA extraction; 1X106 HBECs, 2X106 
PBMCs, 1X106 monocytes, 2X106 lymphocytes, 3X106 neutrophils and 1X106 
macrophages. All the RNA processing and detection were done as described in the 
methods section. 
 
3.2.2 Western blotting 
Primary antibodies used, purified anti-XBP-1s Antibody (BioLegend) at 1/250 
dilution, HPRT Antibody (Santa Cruz) at 1/500 dilution. The secondary antibody used, 
Goat anti-Rabbit IgG (H+L) Poly-HRP Secondary Antibody (Thermo Fisher Scientific), 
was diluted at 1/5000 in PBST. The complete protein detection process through 
Western blotting was done as described in the methods section. 
 
3.2.3 Flow cytometry 
For the detection of IRE1, pIRE1, PERK and ATF6 in the HBECs the next steps 
were followed; the intracellular expression of IRE1, pIRE1, PERK and ATF6 was 
studied by flow cytometry analysis in the CF HBECs. Corresponding isotype controls 
for all the antibodies were used. Cells were cultured and detached, as previously 
mentioned in the methods section. Then, cells were centrifuged at 300g for 5 min, 
washed with PBS, and fixed (4% paraformaldehyde) and permeabilised (BD 
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Cytofix/Cytoperm) for 15min, as recommended by the manufacturer. Cells were 
washed and resuspended in BSB with Human IgG (Merck I2511) and Mouse serum 
(M5905) to ‘Fc Block’ the cells for 10min. After non-specific binding was reduced by 
blocking the cells, the conjugated specific antibodies IRE1(GeneTex), 
pIRE1(Santa Cruz), PERK (Santa Cruz) and ATF6 (Santa Cruz), or their isotype 
controls, Rabbit IgG (GeneTex),  Normal mouse IgG1 (Santa Cruz), were added to 
the cells at a concentration of 5 to 10 L/106 cells, as recommended by each 
manufacturer. Cells were incubated with the antibodies, for 30 minutes on ice in the 
dark and 30,000 events were captured per sample. Cells were acquired into a 
CytoFLEX flow cytometer (Beckman Coulter). Any other flow cytometry process was 
done as described in the methods section. 
 
3.2.4 Cellular stimulations 
HBECs, PBMCs, lymphocytes, and monocytes were left unstimulated or 
stimulated with LPS (10ng/ml), Tn (5g/ml) and Tg (300 nM) for 4 hours. Neutrophils 
were stimulated with LPS (10ng/ml), Tn (2g/ml) and Tg (150 nM). Macrophages were 
cultured and activated, as mentioned in the methods section and stimulated with LPS 
(100ng/ml). 
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3.3 Results 
 
3.3.1 UPR activation in CF HBEC lines 
First, UPR activation was analysed in the BEAS-2BWT/WT, CuFi-1F508/F508, 
CuFi-4G551D/F508 and IB3-1F508/W1282X cell lines. The induction of the UPR was 
assessed by doing a time-course experiment, using the UPR inducer tunicamycin (Tn) 
for 2, 4 and 8 h in the BEAS-2B cell line. As expected, IRE1, PERK, XBP1s, ATF4, 
CHOP and BiP were upregulated upon stimulation with Tn, and the expression of the 
transcripts reached a significant fold change after 4 h of stimulation (Figure 11). Then, 
we compared the expression of BIP, IRE1, ATF6, PERK, XBP1s, XBP1u, eIF2, 
ATF4, CHOP and GADD34 in the CF cell lines at basal conditions. In the CuFi-1 cell 
line, all the transcripts were significantly upregulated, when compared to the WT 
control (Figure 12). We observed that only BIP, XBP1s, eIF2 and CHOP were 
significantly upregulated in the heterozygous CuFi-4 cell line (Figure 12). Surprisingly, 
in IB3-1 cell line, we detected a downregulation of IRE1 and XBP1s transcripts, 
suggesting that UPR activation is dependent on the type of class mutation present in 
the CF cells (Figure 12). While IL-6 was significantly upregulated in all CF cell lines, 
this particular aspect will be discussed in section 4.3.1, entitled “Upregulation of 
inflammatory cytokines in CF HBECs”. 
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Figure 11 – UPR induction time course. 
UPR activation was induced using Tn for 2, 4 and 8 hours in the BEAS-2B cell line. 
IRE1, PERK, ATF6, XBP1s, ATF4, CHOP and BiP expression were analysed by 
qPCR. mRNA expression is represented by fold change, compared to the mean basal 
expression of each gene. After the time course experiment was completed, cells were 
lysed, and RNA extracted, as described in the methods section. Paired Student's t-
test *p < 0.05, **p < 0.01, ***p < 0.001. n = 3 biological replicates. 
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Figure 12 – UPR activation in CF HBECs 
UPR activation was measured in the BEAS-2B, IB3-1, CuFi-1, and CuFi-4 cell lines. 
The mRNA expression of BIP, IRE1, ATF6, PERK, XBP1s, XBP1u, eIF2, ATF4, 
CHOP, GADD34 and IL-6 was analysed by qPCR. Relative mRNA expression was 
calculated using the Ct method with HPRT and PPIA as the housekeeping genes. 
Statistical significance was determined using Two-way ANOVA, Dunnett's test *p < 
0.05, **p < 0.01, ***p < 0.001. n = 4 biological replicates for all cell lines. Part of these 
data has been previously published [30].   
 
Next, we investigated the response of the CF cell lines when challenged to LPS, Tn 
and thapsigargin (Tg), the latter being a stronger UPR inductor. LPS stimulation did 
not induce a significant response in BIP, IRE1, ATF6 nor PERK transcripts in any of 
the cell lines (Figure 13); however, there were some interesting findings regarding Tn 
and Tg stimulations. Both drugs, Tn and Tg, induced the upregulation of BIP in all cell 
lines (Figure 13A). When stimulated with Tn and Tg, the CF CuFi-1 and CuFi-4 cells 
lines lost statistical significance when compared to the WT control BEAS-2B (P<0.5) 
(Figure 13A). The expression of IRE1 in the CuFi-1 cell line was still significant when 
compared to the WT control after stimulation with Tn and Tg, PERK expression was 
only significant after Tg stimulation, and ATF6 expression was not significant after 
stimulation with any of the drugs (Figure 13B-D). Interestingly, while the CF CuFi-4 
cell line was not significantly different to the WT control cell line, under basal 
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conditions, the CuFi-4 cell line reached a significantly high level of expression of the 
IRE1 transcript after stimulation with the drugs. (Figure 13B-D). 
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Figure 13 – Activation the BIP, IRE1, ATF6 and PERK. 
UPR activation was measured in the BEAS-2B, IB3-1, CuFi-1, and CuFi-4 cell lines 
after stimulation with LPS (100ng/ml), Tn (5g/ml) and Tg (300 nM) for 4 hours. The 
mRNA expression of BIP, IRE1, ATF6, and PERK was analysed by qPCR. Relative 
mRNA expression was calculated using the Ct method with HPRT and PPIA as the 
housekeeping genes. All the comparisons were made versus the BEAS-2B cell line 
comparing each stimulation accordingly. Statistical significance was determined using 
unpaired independent student's t-test, for each of the stimulations. *p < 0.05, **p < 
0.01, ***p < 0.001. n=4 biological replicates for all cell lines. 
 
The IB3-1 cell line displayed no difference in the expression of ATF6 nor BiP. 
Surprisingly, the IB3-1 cells showed a downregulation of IRE1 under basal conditions 
and after Tg stimulation (Figure 13B-D). Finally, while the expression levels of PERK 
were not different under basal conditions, both levels were significantly downregulated 
after stimulation with Tn and Tg (Figure 13B-D). We then explored XBP1s, XBP1u, 
eIF2CHOP and GADD34 expression, all of them being downstream of the UPR 
signalling pathway (Figure 14). XBP1s was strongly upregulated under basal 
conditions in the CuFi-1 and CuFi-4 cell lines and downregulated in the IB3-1 cell lines 
(Figure 14A). When the cells were stimulated with Tn and Tg they all strongly 
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upregulated XBP1s (Figure 14A). This finding suggests that the amount of ER stress 
that can be induced in a cell is limited, and the higher amounts of ER stress, already 
present on the CF cell lines, cannot be further increased. While the amount of XBP1s 
was significantly lower in the IB3-1 cell lines, XBP1u was upregulated after stimulation 
with Tn and Tg (Figure 14B). Moreover, in the CuFi-1 and CuFi-4 cell lines, XBP1u 
was downregulated upon addition of Tn and Tg (Figure 14B). The same observation 
as that seen with XBP1s, was noted in eIF2 and CHOP transcripts, with a degree of 
significance (P<0.05) being lost after stimulation with both drugs (Figure 14C and D). 
The compound heterozygous IB3-1 cell line revealed downregulation of eIF2 after 
stimulation with Tn and Tg, and downregulation of GADD34 only after Tg stimulation 
(Figure 14C and E). The two CuFi-1 and CuFi-4 cell lines showed significantly higher 
levels of GADD34, after Tg stimulation, when compared to the WT control (Figure 
14E). Finally, we evaluated the expression of IRE1, pIRE1, ATF6 and PERK 
proteins in all HBEC lines. As shown previously higher levels of mRNA expression of 
IRE1and XBP1s were consistently seen in the CuFi-1 and CuFi-4 cell lines. 
Furthermore both, IRE1 and pIRE1 were upregulated in the CF cell lines when 
compared to the BEAS-2B cells (Figure 15A, B and E). In addition, ATF6 and PERK 
expression were also both upregulated in the CuFi-1 and CuFi-4 cell lines (Figure 
15C-E). No significant differences were detected in the IB3-1 cell line when compared 
with the WT cell line. 
 
 
 
 71 
 
 
 72 
 
Figure 14 – Activation the XBP1s, XBP1u, eIF2CHOP and GADD34. 
UPR activation was measured in the BEAS-2B, IB3-1, CuFi-1, and CuFi-4 cell lines 
after stimulation with LPS (100ng/ml), Tn (5g/ml) and Tg (300 nM) for 4 hours. The 
mRNA expression of XBP1s, XBP1u, eIF2, CHOP and GADD34 was analysed by 
qPCR. Relative mRNA expression was calculated using the Ct method with HPRT 
and PPIA as the housekeeping genes. All the comparisons were made versus the 
BEAS-2B cell line, comparing each stimulation accordingly. Statistical significance 
was determined by using unpaired independent Student's t-test for each of the 
stimulations. *p < 0.05, **p < 0.01, ***p < 0.001. n=4 biological replicates for all cell 
lines. 
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Figure 15 – IRE1, pIRE1, ATF6 and PERK protein expression in HBECs 
Single cells were gated and then used to measure the mean fluorescent intensity (MFI) 
of each cell line, by flow cytometry; IRE1 (A), pIRE1(B), ATF6 (C) and PERK (D) 
were measured in the HBECs. The fluorophore measured are shown in the respective 
panels and also in the methods section. The MFI is represented in panel (E). All 
antibodies were normalised with their respective isotype controls in each cell line. 
Statistical significance was determined using unpaired independent Student's t-test. 
*p < 0.05, **p < 0.01, ***p < 0.001. n=4 biological replicates for all cell lines. 
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3.3.2 UPR activation in PBMCs from patients with CF 
After finding that CF HBECs displayed a unique UPR activation, mainly 
involving the IRE1-XBP1 pathway, we analysed UPR activation in primary PBMCs 
from patients with CF at basal conditions, after LPS challenge and under ER stress 
conditions induced by both, Tn and Tg. Under basal conditions, IRE1 and GADD34 
were significantly upregulated in PBMCs from CF patients, while IL-6 was 
downregulated (Figure 16). Interestingly, stimulation with LPS induced a significant 
upregulation in BiP, IRE1, XBP1s, ERdj4, ATF4, GADD34, TNF, and IL-6 transcripts 
of PBMCs from CF patients when compared to those from HC volunteers (Figure 16). 
Furthermore, we found similar findings after ER stress induction by Tn with BiP and 
IRE1 significantly upregulated and after stimulation with Tg with significantly higher 
expression in PERK and XBP1s (Figure 17). 
 
Figure 16 – UPR activation in primary PBMCs from patients with CF 
mRNA relative expression of ER stress and UPR markers BiP, IRE1, PERK, XBP1s, 
ERdj4, ATF4, CHOP, GADD34, TNF, and IL-6 were measured in PBMCs from HC 
volunteers (n=8) and patients with CF (n=14) at basal conditions and stimulated with 
LPS (10 ng/ml) for 4 h. All n values represent biologically independent samples. 
Statistical comparisons were performed by unpaired independent Student's t-test, *p 
< 0.05, **p < 0.01, ***p < 0.001; ND, not detected. These data have been published 
by the author [30]. 
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Figure 17 – ER stress in PBMC stimulated with Tn and Tg 
UPR activation was measured in primary PBMCs from HC individuals (n=8) and 
patients with CF (n=14) at basal conditions, stimulated with Tn (5 g/ml), or Tg 
(300nM) for 4 hours. (A-H). BiP, IRE1, PERK, XBP1s, ERdj4, ATF4, CHOP and 
GADD34 were measured by qPCR. Statistical comparisons were performed by 
unpaired independent Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. These 
data have been published by the author [30] 
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3.3.3 No difference in UPR activation in lymphocytes 
PBMCs are composed of a mixed population of different immune cells. 
Therefore, any differences found within PBMCs in the patients’ samples could be due 
to the heterogeneous composition of PBMCs. To identify ER stress abnormalities in 
immune cells from patients with CF, I isolated different subsets of immune cells. 
Isolation of lymphocytes, neutrophils and monocytes, with further differentiation of 
monocytes to monocyte-derived macrophages was performed in this research project. 
Lymphocytes from CF patients did not show any significant differences in any of the 
transcripts measured, either at basal conditions or after LPS stimulation (Figure 18). 
The same was observed after stimulation with Tn and Tg (Figure 19). 
 
 
Figure 18 – UPR gene expression in lymphocytes from patients with CF 
mRNA relative expression of ER stress and UPR markers BiP, IRE1, PERK, XBP1s, 
ERdj4, ATF4, CHOP, GADD34, TNF, and IL-6 were measured in lymphocytes from 
HC volunteers (n=6) and patients with CF (n=6) at basal conditions and stimulated 
with LPS (10 ng/ml) for 4 h. All n values represent biologically independent samples. 
Statistical comparisons were performed by unpaired independent Student's t-test, *p 
< 0.05, **p < 0.01, ***p < 0.001; ND, not detected. These data have been published 
by the author [30]. 
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Figure 19 – ER stress in lymphocytes stimulated with Tn and Tg  
UPR activation was measured in primary lymphocytes from HC individuals (n=6) and 
patients with CF (n=6) at basal conditions, stimulated with Tn (5 g/ml), or Tg (300nM) 
for 4 hours. (A-H). BiP, IRE1, PERK, XBP1s, ERdj4, ATF4, CHOP and GADD34 
were measured by qPCR. Statistical comparisons were performed by unpaired 
independent Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. 
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3.3.4 BiP, IRE1, ATF4 and CHOP upregulation in neutrophils 
After evaluation of ER stress in lymphocytes, we then analysed the same 
markers in neutrophils from the same patients with CF. Neutrophils carrying CFTR 
mutations presented upregulation of several ER stress markers. These multinucleated 
cells showed raised levels of BiP, IRE1, ATF4, and CHOP at basal conditions, where 
only BiP and CHOP were significantly upregulated after stimulation with LPS (Figure 
20). Stimulations of these cells with 5 g/ml of Tn or 300nM of Tg drastically reduced 
the survival rate of the cells. Therefore, adjusted concentrations of the drugs were 
administrated to these cells. Neutrophils from CF patients still demonstrated 
heightened levels of BiP, IRE1, ATF4, and CHOP following the administration of the 
drugs, with the only exception being ATF4, which was not significantly altered post Tg 
stimulation (Figure 21). 
 
Figure 20 – UPR gene expression in neutrophils from patients with CF 
mRNA relative expression of ER stress and UPR markers BiP, IRE1, PERK, XBP1s, 
ERdj4, ATF4, CHOP, GADD34, TNF, and IL-6 were measured in neutrophils from HC 
volunteers (n=6) and patients with CF (n=6) at basal conditions and stimulated with 
LPS (10 ng/ml) for 4 h. All n values represent biologically independent samples. 
Statistical comparisons were performed by unpaired independent Student's t-test, *p 
< 0.05, **p < 0.01, ***p < 0.001; ND, not detected. These data have been published 
by the author [30]. 
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Figure 21 – ER stress in neutrophils stimulated with Tn and Tg  
UPR activation was measured in primary neutrophils from HC individuals (n=6) and 
patients with CF (n=6) at basal conditions, stimulated with Tn (2 g/ml), or Tg (150nM) 
for 4 hours. (A-H). BiP, IRE1, PERK, XBP1s, ERdj4, ATF4, CHOP and GADD34 
were measured by qPCR. Statistical comparisons were performed by unpaired 
independent Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. 
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3.3.5 IRE1, PERK, ERdj4, ATF4, CHOP and GADD34 upregulation in monocytes 
Human monocytes were studied to assess whether UPR perturbations existed 
within these phagocytic cells. Monocytes from patients with CF exhibited higher levels 
of IRE1 and ATF4 under basal conditions, similar to those seen in neutrophils 
(Figure 22). When monocytes were stimulated with LPS, more significant differences 
were revealed with regard to the expression of IRE1, PERK, ERdj4, CHOP, GADD34 
and TNF (Figure 22). These findings suggest that cells of myeloid origin, carrying 
CFTR mutations, exhibit similar perturbations at the transcriptional level, with IRE1 
being the most predominantly affected. Next, monocytes were stimulated with the 
UPR inducers, Tn and Tg, as previously described. After stimulation with Tn, IRE1, 
ATF4, CHOP and XBP1s transcripts were significantly upregulated in the CF 
monocytes (Figure 23). Furthermore, cells stimulated with Tg only showed a 
significant upregulation of IRE1 and ATF4, when compared to the HC cells (Figure 
23). All these findings support the idea of abnormal regulation of the UPR signalling 
pathways in myeloid cells with CFTR mutations. 
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Figure 22 – UPR gene expression in monocytes from patients with CF 
mRNA relative expression of ER stress and UPR markers BiP, IRE1, PERK, XBP1s, 
ERdj4, ATF4, CHOP, GADD34, TNF, and IL-6 were measured in monocytes from HC 
volunteers (n=6) and patients with CF (n=6) at basal conditions and stimulated with 
LPS (10 ng/ml) for 4 h. All n values represent biologically independent samples. 
Statistical comparisons were performed by unpaired independent Student's t-test, *p 
< 0.05, **p < 0.01, ***p < 0.001; ND, not detected. These data have been published 
by the author [30]. 
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Figure 23 – ER stress in monocytes stimulated with Tn and Tg  
UPR activation was measured in primary monocytes from HC individuals (n=6) and 
patients with CF (n=6) at basal conditions, stimulated with Tn (5 g/ml), or Tg (300nM) 
for 4 hours. (A-H). BiP, IRE1, PERK, XBP1s, ERdj4, ATF4, CHOP and GADD34 
were measured by qPCR. Statistical comparisons were performed by unpaired 
independent Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. 
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3.3.6 The IRE1-XBP1 pathway is overactive in CF M1 macrophages 
Monocytes are the natural precursors of macrophages when derived from 
blood; therefore, we differentiated blood monocytes into macrophages, then, 
macrophages were polarised into M1 or M2 like-phenotype using LPS/IFNand IL-
4/IL-13, respectively, and characterised by flow cytometry as described in the methods 
section and in Figure 24. While the polarisation ratios will be discussed later, we did 
not find any significant difference in the proportion of polarised M1 macrophages in 
patients with CF; however, the inflammatory profile of M1 macrophages was 
significantly increased when compared to HC macrophages. 
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Figure 24 – Differentiation process of M1/M2 macrophages 
Human blood monocytes were grown into macrophages, for 6 days, with GM-CSF 20 
ng/ml or M-CSF 20 ng/ml. M1 macrophages were activated by stimulating the cells 
with 100 ng/ml human IFN, and 50 ng/ml LPS. M2 macrophages were activated by 
stimulating cells with 20 ng/ml IL-13 and 20 ng/ml IL-4 (A). Macrophages were 
characterized as M1-type (markers- CD14+, HLA-DR+, CD274+, CD86+ TNFHI) or 
M2-type (markers- CD14+, HLA-DR−, CD206+ and IL-10HI) as described in the 
methods (B). This figure has been published by the author [30]. 
 
 
Therefore, it was hypothesised that the abnormal inflammatory profile seen in CF M1 
macrophages could be explained by intrinsic cellular defects caused by the CFTR 
mutations, which are also seen in the monocytes. Consequently, we analysed UPR 
activation in fully-activated M1 macrophages under basal conditions, meaning that M1 
macrophages were activated for 24 h with LPS/IFN followed by a second challenge 
with LPS when mentioned. Under basal conditions, a significant upregulation of BIP, 
XBP1s, ERdj4, TNF and IL-6 transcripts was observed (Figure 25), while, after LPS 
stimulation we detected high levels of BIP, XBP1s, TNF and IL-6, with downregulation 
of PERK (Figure 25). As already performed with the other immune cells, M1 
macrophages were also stimulated with Tn and Tg to assess differences in cell 
response under stress conditions. The amount of BIP, XBP1s and GADD34 transcripts 
were significantly elevated after both stimulations, while only ATF4 transcription levels 
were upregulated post Tg stimulation (Figure 26). 
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Figure 25 – UPR gene expression in M1 macrophages from patients with CF 
mRNA relative expression of ER stress and UPR markers BiP, IRE1, PERK, XBP1s, 
ERdj4, ATF4, CHOP, GADD34, TNF, and IL-6 were measured in M1 macrophages 
from HC volunteers (n=9) and patients with CF (n=9) at basal conditions and 
stimulated with LPS (100 ng/ml) for 4 h. All n values represent biologically independent 
samples. Statistical comparisons were performed by unpaired independent Student's 
t-test, *p < 0.05, **p < 0.01, ***p < 0.001; ND, not detected. These data have been 
published by the author [30]. 
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Figure 26 – ER stress in M1 macrophages stimulated with Tn and Tg  
UPR activation was measured in M1 macrophages from HC individuals (n=9) and 
patients with CF (n=9) at basal conditions, stimulated with Tn (5 g/ml), or Tg (300nM) 
for 4 hours. (A-H). BiP, IRE1, PERK, XBP1s, ERdj4, ATF4, CHOP and GADD34 
were measured by qPCR. Statistical comparisons were performed by unpaired 
independent Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. 
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The elevated levels of XBP1s were confirmed by running a conventional RT-PCR gel, 
which revealed the presence of XBP1s in the majority of the CF M1 macrophage 
samples (Figure 27A). Next, we measured the protein levels of XBP1s in CF M1 
macrophages. Levels of XBP1s were also significantly higher in M1 macrophages 
from CF patients, compared to the HC (Figure 27B and C). These findings suggest 
that the IRE1-XBP1s signalling pathway is abnormally upregulated in M1 
macrophages from CF patients. 
 
 
Figure 27 – XBP1s in M1 macrophages from CF patients 
(A) XBP1s was measured by RT-PCR in M1 macrophages from HC volunteers (n=7) 
and patients with CF (n=9). (B and C) XBP1s protein levels were measured in M1 
macrophages from HC individuals (n=4) and patients with CF (n=5) by Western 
blotting. Cell lysates were immunoblotted for XBP1s and HPRT (B), XBP1s was 
normalized to HPRT, and the ratios were compared to the levels of HC (C). Statistical 
comparisons were performed unpaired independent Student's t-test, *p < 0.05, **p < 
0.01, ***p < 0.001 (C). Part of this figure was produced by Mr Johnathan Holbrook and 
published by the author [30]. 
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3.3.7 XBP1s is not induced in CF M2 macrophages 
While XBP1s was commonly upregulated after LPS stimulation in 
macrophages, we also quantified XBP1s at the protein level in M2 macrophages from 
CF patients [151]. It was found that XBP1s was not present in fully activated M2 
macrophages (Figure 28). This finding demonstrates that XBP1s overexpression is 
only present in M1 macrophages from patients with CF. 
 
 
Figure 28 – XBP1s is absent in M2 macrophages from CF patients 
XBP1s protein levels were measured in M2 macrophages from HC individuals (n=4) 
and patients with CF (n=5) by Western blotting. Cell lysates were immunoblotted for 
XBP1s and HPRT. Statistical comparisons were performed unpaired independent 
Student's t-test, *p < 0.05, **p < 0.01, ***p < 0.001. This figure was produced with the 
help of Mr Johnathan Holbrook and published by the author [30]. 
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3.4 Discussion 
 
Clear evidence of abnormal UPR activation was found in cells with CFTR 
mutations. Interestingly, these abnormalities were only found in innate immune cells. 
It has been previously shown that activation of the UPR decreases CFTR expression 
[202]. Therefore, this UPR activation may be contributing to the reduced level of CFTR 
expression seen in cells with CF mutations. Furthermore, chronic UPR activation can 
induce the production of several pro-inflammatory cytokines, such as IL-1, IL-6 and 
TNF, and this will be discussed in the next chapter [151]. The CF HBECs CuFi-1, 
F508/F508, and CuFi-4, F508/G551D, showed significant upregulation of several 
markers of ER stress, with the IRE1-XBP1 pathway being the most consistent. 
Remarkably, the CuFi-1 cell line revealed upregulation in all the ER stress markers 
studied here, while the CuFi-4 cell line only presented increased levels of BIP, XBP1s, 
eIF2  and CHOP. These findings suggest that the amount of ER stress present in the 
CF cell lines may be specifically associated with particular genotypes. Surprisingly, 
the IB3-1 cell line, carrying a class type I mutation, showed decreased levels of PERK 
and IRE1, with no change in any other marker, as opposed as those findings 
described by Blohmke et al. [172], where the authors found raised levels of XBP1s. 
The discrepancies found in here could be due to differences between the cell lines, as 
these come from different individuals or the culturing conditions. In fact, to validate 
these findings, a collaboration has been established with Professor Martinon, to create 
a BEAS-2B cell line F508 homozygous for the CFTR and BEAS-2B CFTR-KO, by 
using CRISPR/Cas9. These cell lines will provide us with direct answers about 
whether the mutated F508 CFTR is directly associated with the activation of the UPR.  
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Considering that the CuFi-1 cell line carries two copies of the CFTR, with F508 
mutations then, in theory, this could be the cell line with more misfolded protein, and 
thus more ER stress. Indeed, it was confirmed that, under basal conditions, CuFi-1 
cells showed significantly higher expression of BiP, IRE1, PERK, and ATF6, 
suggesting that this cell line is under chronic ER stress. These findings are in line with 
the observations that CuFi-4 cells still show UPR activation (Figure 12), but to a lesser 
than the CuFi-1. It is essential to mention that the IB3-1 cell line also carries one CFTR-
F508 allele, implying that ER stress is hypothetically present, mainly caused by 
misfolded protein accumulation; however, this was not the case and the absence of 
ER stress in the IB3-1 cells could be due to degradation of the CFTR-F508 in a 
similar manner to the CFTR-W1282X, where total CFTR degradation results in no 
misfolded protein accumulation. Another possibility is that different class mutations are 
regulated in a different manner with similar consequences. 
When UPR activation in PBMCs from CF patients was investigated, no significant 
differences were observed in XBP1s expression under basal conditions, as described 
by Blohmke et al. [172]; nevertheless, we observed a significant increase in XBP1s 
after stimulation with LPS and Tn in PBMCs from patients with CF. This difference 
could be due to the choice of technique used in the isolation of the PBMCs, the media 
used for culturing the cells, or the timing for RNA collection. While I believe that there 
is chronic UPR activation in individual immune cells harbouring CFTR mutations, this 
ER stress is low-grade in nature. Under basal conditions, we detected a consistent 
upregulation of IRE1in PBMCs, neutrophils and monocytes, suggesting that this 
particular pathway is the most affected in innate immune cells with CFTR mutations. 
Moreover, most of these differences were still maintained after LPS, Tn and Tg 
stimulations. Besides IRE1 monocytes showed significant upregulation of ATF4 
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under basal conditions, with upregulation of PERK, ERdj4, CHOP and GADD34 after 
LPS stimulation. These findings suggest that, upon induction of cellular stress through 
LPS, the low-grade ER stress become significantly evident. Despite the fact that 
XBP1s levels were not significantly different in CF monocytes, under basal conditions, 
we observed a significant upregulation of this transcript after stimulating the cells with 
Tn. This finding, aligned with other publications showing that XBP1s is overexpressed 
in alveolar macrophages from patients with CF [113], lead us to investigate ER stress 
in monocyte-derived macrophages. It is essential to mention that the activation of 
lymphocytes with LPS is not ideal in this experimental system, as, for instance, T cells 
require direct cell-to-cell contact with antigen presenting cells to become fully 
activated; however, we still wanted to include these experiments to compare basal ER 
stress and to investigate whether there were any differences after stimulation with LPS 
and any XBP1s, due to some papers reporting the existence of some signalling in 
lymphocytes after TLR4 stimulation [203-205].  
 When monocytes reach the site of infection or inflammation, and as soon as 
they are stimulated with granulocyte-macrophage colony-stimulating factor (GM-CSF) 
or macrophage colony-stimulating factor (M-CSF), they differentiate into monocyte-
derived macrophages [206, 207]. When monocytes are being differentiated on the 
road to become macrophages, their cellular size is enlarged, and this process provides 
these cells with a more exceptional ability to promote inflammation and phagocytosis. 
When we differentiated macrophages and polarised into a M1-like phenotype, they 
showed a consistent upregulation in XBP1s. M1 macrophages from CF patients 
showed significantly increased levels in XBP1s, BIP, TNF and IL-6, under basal 
conditions and after a second LPS challenge. The XBP1s transcript levels were 
confirmed by Western blotting showing a persistent upregulation in XBP1s in the M1 
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macrophages from CF patients. In contrast, M2 macrophages activated with IL-4/IL-
13 did not show any difference in XBP1s protein expression. Altogether, these findings 
suggest that the IRE1-XBP1 signalling pathway is overactive in M1 macrophages 
from CF patients with potential implications in inflammation.  
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Chapter 4 – Inflammation and the UPR in Cystic 
Fibrosis 
4.1 Introduction 
 
Inflammation is a major component in the pathogenesis of CF, and, as described 
before, it can be induced via the UPR signalling pathway. The lung is a complex 
microenvironment and, in CF, this environment is altered, thereby favouring bacterial 
colonisation. As already demonstrated, an atypical UPR activation exists in CF and it 
is CFTR dependent, in the case of HBECs, and also cell-specific, as in the case of 
innate immune cells. Our results are in line with other reports, showing that CF alveolar 
macrophages have increased levels of XBP1s along with heightened production of 
TNF and IL-6, as will be described later in this chapter [113].  
Stimulation of CF HBECs and PBMCs, from CF patients, with the TLR5 ligand, 
flagellin, results in increased levels of IL-6 release without PERK/eIF2 induction 
[172]. In a different study, in non-CF HBECs, exposure to P. aeruginosa conditioned 
medium induced the expression of XBP1s, CHOP, BiP, and GADD34 [208]. This 
indicates that the UPR signalling pathway is an important innate cellular mechanism 
in HBECs that helps in the induction of the inflammatory response. Furthermore, the 
UPR plays a significant role in the regulation of inflammation in immune cells, as 
described before [151]. Therefore, based on our evidence that HBECs and innate 
immune cells showed an atypical UPR activation, with consistent upregulation of 
IRE1we investigated the consequences of this upregulation involving two important 
pro-inflammatory cytokines increased in CF, TNF and IL-6. 
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4.2 Methods 
 
4.2.1 RNA isolation and detection 
All the RNA processing and detection were performed, as described in the 
methods section. The following cell numbers were used for RNA extraction; 1X106 
HBECs, 2X106 PBMCs, 1X106 monocytes, 2X106 lymphocytes, 3X106 neutrophils and 
1X106 macrophages. 
 
4.2.2 Flow cytometry 
For the characterisation of M1 and M2 macrophages, the following protocol was 
used. Negatively selected monocytes, as described in the main methods, were 
cultured in complete RPMI medium (Merck) to generate either M1 or M2 macrophages 
(Figure 24). For M1/M2 macrophage characterization using flow cytometry, 
monocytes were seeded at a density of 1 ×106 cell/ml and were cultured in tissue 
culture-treated 6 well plates, then stimulated and activated with their respective 
factors. On day 7 cells were washed twice with DBPS without Ca2+ and Mg2+ and 
detached, using DPBS with EDTA 10 mM for M2 macrophages, or Accutase 
(ThermoFisher) for M1 macrophages. Cells were washed twice with DPBS (2% FBS) 
and resuspended in BSB, with human and mouse serum for 30 min on ice. Cells were 
stained with the surface markers for M1-type (CD14+, HLA-DR+, CD274+ and CD86+) 
and M2-type (CD14+, HLA-DR-, and CD206+) for 30 min on ice. Finally, cells were 
washed, fixed (4% paraformaldehyde) and permeabilised (BD Cytofix/Cytoperm) for 
20 min, as recommended by the manufacturer. The intracellular markers, IL-10 and 
TNF, were then added for a further 15 min. After the final wash, the cells were 
resuspended in BSB in FACS collection tubes. All antibodies used are listed in detail 
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in the table of reagents (Table 5). All other flow cytometry procedures were done as 
described in the main methods section. 
 
4.2.3 Cytokine expression 
Cytokine levels from cell cultured media were detected by the IL-6, TNF, and 
IL-10 ELISAs kits, listed in the table of reagents, following the manufacturer’s 
recommendations and as described in the methods section. All supernatants were 
collected after each cellular stimulation and stored at -80°C until required. 
 
4.2.4 Cellular stimulations 
HBECs, PBMCs, lymphocytes, and monocytes were left unstimulated or 
stimulated with LPS (10ng/ml), Tn (5g/ml) and Tg (300 nM) for 4 hours. Neutrophils 
were stimulated with LPS (10ng/ml), Tn (2g/ml) and Tg (150 nM). Macrophages were 
cultured and activated, as mentioned in the main methods section, and stimulated with 
LPS (100ng/ml). When used, the IRE1 inhibitors 4μ8c (50 μM) and MKC-3946 (10 μM) 
were administrated 30 min before any activation. 
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4.3 Results 
 
4.3.1 Upregulation of IL-6 in CF HBECs 
As seen in the previous chapter, the UPR signalling pathway is upregulated in 
CF HBECs, particularly in the CuFi-1 cell line. Therefore, the consequences of this 
UPR activation regarding the production of IL-6, which is upregulated by the 
IRE1/XBP1 signalling pathway were explored [151]. As seen before, under basal 
conditions, CF HBECs showed significantly higher levels of IL-6 (Figure 29). 
Stimulation of HBECs with the UPR inducer Tn resulted in a reduction of IL-6 
expression in the BEAS-2B and the IB3-1 cell lines, and an increase in the CuFi-1 and 
CuFi-4 cell lines when compared to the basal state of each cell line (Figure 29). In 
contrast, stimulation with Tg led to an increased expression of IL-6 in all cells, with a 
significant increase in the CuFi-1 and CuFi-4 CF cell lines, when compared to the WT 
control (Figure 29). mRNA expression of the pro-inflammatory cytokine IL-1B was 
also measured in all the HBECs, and preliminary results suggest that this cytokine is 
upregulated under basal condition in the CF HBEC lines [209]. The production of IL-6 
has been associated with the transcription factor XBP1s [151, 152]; therefore, it was 
investigated whether the IRE1 inhibitor, 48c, would reduce the expression of IL-6. 
Pre-treatment of the CuFi-1 and BEAS-2B cell lines with the IRE1 inhibitor abolished 
the expression and the secretion of IL-6 (Figure 30). These inhibitory effects were still 
seen after LPS and Tg stimulation in both HBEC lines (Figure 30). In summary, the 
elevated IL-6 expression, seen in CF HBECs, can be blocked by inhibition of the 
IRE1/XBP1 signalling pathway. 
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Figure 29 – IL-6 expression in HBECs with CF mutations  
IL-6 expression was measured in the BEAS-2B, IB3-1, CuFi-1, and CuFi-4 cell lines 
after stimulation with LPS (100 ng/ml), Tn (5g/ml) and Tg (300 nM) for 4 hours. mRNA 
expression was analysed by qPCR. All comparisons were made versus the BEAS-2B 
cell line, comparing each stimulation accordingly. Statistical significance was 
determined using unpaired independent Student's t-test for each of the stimulations. 
*p < 0.05, **p < 0.01, ***p < 0.001. n=4 biological replicates for all cell lines. 
 
 
 
Figure 30 – IRE1 inhibition reduces IL-6 in HBECs.  
IL-6 expression and production were measured in response to LPS (100 ng/ml) and 
Tg (300 nM) for 4 h measuring IL-6 mRNA (A) and IL-6 cytokine levels (B); when 
referred, the IRE1 inhibitor, 48c (50 μM), was used 30 min before each stimulation. 
All data are presented as mean ± SEM and mRNA data represented by logarithmic 
scale base 10. Statistical significance was determined by using paired Student's t-test. 
*p < 0.05, **p < 0.01, ***p < 0.001. n=4 biological replicates for all cell lines. These 
data have been published by the author [30].  
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4.3.2 Expression of TNF and IL-6 in lymphocytes and neutrophils 
 
Expression of TNF and IL-6 is not a standard characteristic of lymphocytes; 
however, we wanted to investigate the mRNA levels of these two cytokines under 
basal conditions and after LPS, Tn and Tg stimulations. While activation of 
lymphocytes with LPS is not ideal, for the reasons indicated before, I still wanted to 
evaluate whether there was any response to this stimulation. Lymphocytes showed a 
modest induction of TNF and a substantial IL-6 mRNA induction after LPS stimulation, 
with no significant differences between groups (Figure 31A). Lymphocytes treated 
with Tn and Tg displayed a modest but significant reduction in the expression of TNF, 
correspondingly (Figure 31B). The levels of expression of IL-6 was not detectable 
under basal conditions; nevertheless, upon stimulation with Tn and Tg, an increase in 
IL-6 mRNA was observed in these cells, with no significant differences observed 
between the two groups (Figure 31C). 
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Figure 31 – TNF and IL-6 expression in lymphocytes.  
TNF and IL-6 expression were measured in response to LPS (10 ng/ml) (A), after Tn 
(5g/ml) and Tg (300 nM) (B and C) for 4 h in lymphocytes from HC (n=6) and patients 
with CF (n=6). All data are presented as mean ± SEM and mRNA data represented 
by logarithmic scale base 10. Statistical comparisons were performed by unpaired 
independent Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. ND (not detected). 
 
Next, TNF and IL-6 expression was evaluated in neutrophils. No significant differences 
were observed in these multinucleated cells, either at basal conditions or after LPS 
activation (Figure 32A). increased levels of TNF mRNA were induced by LPS 
stimulation; however, we did not detect IL-6 expression in these cells (Figure 32A). 
Stimulation of the cells with Tn or Tg induced a modest change in the levels of TNF 
(Figure 32B). Altogether, no differences were found in TNF or IL-6 expression 
between the HC and CF group in either lymphocytes or in neutrophils.  
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Figure 32 – TNF and IL-6 expression in neutrophils. 
TNF and IL-6 expression were measured in response to LPS (10 ng/ml) (A), after Tn 
(2g/ml) and Tg (150 nM) (B) for 4 h in neutrophils from HC (n=6) and patients with 
CF (n=6). All data are presented as mean ± SEM and mRNA data represented by 
logarithmic scale base 10. Statistical comparisons were performed by unpaired 
independent Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. ND (not 
detected). 
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4.3.3 Upregulation of TNF in CF monocytes 
Monocytes are important inducers of the inflammatory response, and when 
required, these cells can differentiate into macrophages, to control inflammation in a 
more efficient manner. Monocytes stimulated with LPS showed induction of both 
inflammatory cytokines, TNF and IL-6 (Figure 33A). There were no significant 
differences under basal conditions when the two groups were compared; however, on 
addition of LPS, there was a significant upregulation of TNF in the CF monocytes 
(Figure 33A). When monocytes were stimulated with Tn and Tg, no significant 
differences were observed in these cells (Figure 33B and C). Then to confirm that our 
observations were not related to cellular death, we assessed cellular viability by using 
Annexin V and propidium iodide (PI). Under basal conditions, we observed ~50% of 
intact cells with less than 5% of late apoptotic cells (Figure 34A). Culture of the 
monocytes with the UPR inducer Tg for 4 h, induced early apoptosis in ~90% of the 
monocytes, with no significant differences in late apoptosis (Figure 34B). When 
comparing HC and patients with CF, we observed that upon stimulation of monocytes 
from the CF patients with LPS, Tn and Tg, there was a gradual decrease in the 
percentage of intact cells (Figure 34C). These data suggest that monocytes with 
CFTR mutations are more sensitive to cellular stress. Moreover, the significant 
difference observed in the production of the pro-inflammatory cytokine, TNF, might be 
due to the increased number of early apoptotic cells in the CF monocytes. 
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Figure 33 – TNF and IL-6 expression in monocytes.  
TNF and IL-6 expression were measured in response to LPS (10 ng/ml) (A), after Tn 
(5g/ml) and Tg (300 nM) (B and C) for 4 h in monocytes from HC (n=6) and patients 
with CF (n=6). All data are presented as mean ± SEM and mRNA data represented 
by logarithmic scale base 10. Statistical comparisons were performed by unpaired 
independent Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. 
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Figure 34 – Apoptosis percentage in human monocytes.  
Cell viability was measured using annexin V and propidium iodide (PI). Intact cells, 
early and late apoptosis were measured in HC and CF monocytes. Cells were either 
left untouched or stimulated with LPS (10 ng/ml), Tn (5g/ml) or Tg (300 nM) (B and 
C) for 4 h. HC (n=2) and CF (n=4). All data are presented as mean ± SEM and  
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4.3.4 Deficient polarisation of M2 Macrophages in patients with CF 
In the previous chapter, we observed that M1 macrophages, from patients with 
CF, displayed significantly higher levels of XBP1s, while M2 macrophages did not 
show any differences in expression of this transcription factor (Figure 27Figure 28). 
Therefore, using the same differentiation protocol, we differentiated monocytes to 
macrophages and polarised them into a M1 or M2 phenotype (Figure 24). We 
characterised the macrophages phenotypes based on the surface markers (CD14+, 
HLA-DR+, CD274+ and CD86+) for M1 and (CD14+, HLA-DR-, and CD206+) for M2 
(Figure 24). After polarisation of M2 macrophages from CF patients and HC, we 
observed a significantly lower amount of M2 macrophages in patients with CF, with 
reduced levels of the anti-inflammatory cytokine, IL-10 (Figure 35).  
 
 
Figure 35 – Reduced polarisation of CF M2 macrophages. 
(A) Polarised M2 macrophages (M-CSF, IL-4, and IL-13) from HC volunteers (n=7) 
and patients with CF (n=7) are presented as percentage M2 of total macrophages 
measured by flow cytometry. (B) IL-10 cytokine levels from M2 polarised macrophages 
measured by ELISA. (C) Phenotypic picture of M2 macrophages by light microscopy 
(20X). All data are presented as mean ± SEM. Statistical comparisons were performed 
by Mann-Whitney non-parametric test, *p < 0.05, **p < 0.01, ***p < 0.001. Part of this 
figure was produced by Dr Thomas Scambler, and published by the author [30]. 
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To confirm that the CFTR is expressed in M2 macrophages, we performed a simple 
immunofluorescent (IF) staining of the CFTR and analysed the cells by confocal 
microscopy (Figure 36). We found that the CFTR is expressed in M2 macrophages. 
The CFTR transmembrane protein was detected in both non-permeabilised and cells 
permeabilised with Triton X-100 and saponin (Figure 36). Permeabilised cells showed 
a higher degree of staining when compared to non-permeabilised cells (Figure 36). 
 
 
Figure 36 – CFTR expression in M2 macrophages. 
CFTR expression was analysed by IF in HC M2 macrophages. All images were taken 
using the same parameters. Cells were left either, unpermeabilised, permeabilised 
with Triton X-100 or saponin. Control images show cells incubated with a CFTR 
isotype control antibody. The nucleus was stained with DAPI (blue), the CFTR (green) 
with a specific antibody and actin filaments with phalloidin staining dye (red) (bar=100 
m).   
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4.3.5 TNF and IL-6 are overexpressed in M1 Macrophages from CF patients 
As reported in the previous section, the proportion of M2 macrophages was 
diminished in patients with CF. Phenotypically, M2 macrophages show an enlarged 
shaped (Figure 35C), while M1 macrophages acquire a rounded conformation 
(Figure 37C). In the case of M1 macrophages, we did not observe any significant 
differences in the proportion of these pro-inflammatory cells (Figure 37A); however, 
the amount of IL-6 secreted by these phagocytic cells was significantly increased in 
the patients with CF (Figure 37B). In the same manner as with the M2 macrophages, 
IF of the M1 macrophages was performed to confirm that the CFTR was expressed in 
these myeloid cells. It was confirmed that the CFTR is expressed in the classically 
activated macrophages, with a higher degree of staining on permeabilised cells 
compared to non-permeabilised (Figure 38). 
 
 
Figure 37 – Upregulation of IL-6 in M1 macrophages. 
(A) Polarised M1 macrophages (GM-CSF, LPS and IFN) from HC volunteers (n=7) 
and patients with CF (n=7) are presented as percentage M1 of total macrophages 
measured by flow cytometry. (B) IL-6 cytokine levels from M1 polarised macrophages 
measured by ELISA. (C) Phenotypic picture of M1 macrophages by light microscopy 
(20X). All data are presented as mean ± SEM. Statistical comparisons were performed 
by Mann-Whitney non-parametric test, *p < 0.05, **p < 0.01, ***p < 0.001. Part of this 
figure was produced by Dr Thomas Scambler and published by the author [30]. 
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Figure 38 – CFTR expression in M1 macrophages. 
CFTR expression was analysed by IF in HC M1 macrophages. All images were taken 
using the same parameters. Cells were left either, unpermeabilised, permeabilised 
with Triton X-100 or saponin. Control images were incubated with a CFTR isotype 
control antibody. The nucleus was stained with DAPI (blue), the CFTR (green) with a 
specific antibody and actin filaments with phalloidin staining dye (red) (bar=100 m). 
 
After confirming CFTR expression in human macrophages, we investigated whether 
the CFTR was also expressed in M1 macrophages from patients with CF. We 
observed CFTR expression in M1 macrophages from patients with CF, which was 
comparable to the HC macrophages (Figure 39). Finally, we investigated TNF and IL-
6 expression in M1 macrophages from both groups. TNF and IL-6 expression were 
significantly increased in M1 macrophages, from patients with CF after 24h of 
activation, and subsequently after a second challenge with LPS (Figure 40A). In the 
same manner, the levels these two pro-inflammatory cytokines were still significantly 
increased after stimulation with Tn and Tg (Figure 40B and C). 
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Figure 39 – CFTR expression in CF M1 macrophages. 
CFTR expression was analysed by IF in M1 macrophages. All images were taken 
using the same parameters. HC (n=1) or CF (n=3) M1 macrophages were left either, 
unpermeabilised, permeabilised with Triton X-100 or saponin. Control images were 
incubated with a CFTR isotype control antibody. The nucleus was stained with DAPI 
(blue), the CFTR (green) with a specific antibody and actin filaments with phalloidin 
staining dye (red) (bar=50 m). 
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Figure 40 – Upregulation of TNF and IL-6 in CF M1 macrophages.  
TNF and IL-6 expression were measured in response to LPS (100 ng/ml) (A), after Tn 
(5g/ml) and Tg (300 nM) (B and C) for 4 h in M1 macrophages from HC (n=9) and 
patients with CF (n=9). All data are presented as mean ± SEM and mRNA data 
represented by logarithmic scale base 10. Statistical comparisons were performed by 
unpaired independent Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. Some of 
these data have been published by the author [30]. 
 
 
 
 
 
 
 
 
 
 
 111
4.3.6 IRE1 inhibition reduces TNF and IL-6 in CF M1 Macrophages 
M1 macrophages from patients with CF were not proportionally different from 
the macrophages from HC volunteers; however, the levels of TNF and IL-6 were still 
significantly higher in the former group (Figure 37). High levels of XBP1s have been 
observed in other disorders, such as TRAPS and RA, in association with an increased 
expression of pro-inflammatory cytokines, as mentioned above. Therefore, we used 
two different IRE1inhibitors to test this hypothesis in the M1 macrophages. Inhibition 
of the RNase domain of IRE1with 48c and MKC-3946 did not affect the polarisation 
ratios of M1 macrophages in either the HC or in the CF group (Figure 41A). To confirm 
that the two inhibitors reduced the inflammation produced by the M1 macrophages, 
we measured IL-6 and TNF at the transcriptional and protein level. As seen before, 
the 48c and MKC-3946 inhibitors showed their strong suppressive effects on XBP1s 
(Figure 41B). Inhibition of the IRE1-XBP1 pathway led to a reduction of IL-6, but not 
TNF in M1 macrophages from patients with CF (Figure 41B). Similarly, as observed 
with the transcription levels, the two inhibitors significantly reduced the higher levels 
of IL-6 produced by M1 macrophages from patients with CF (Figure 41C). While TNF 
was not reduced at the transcriptional level, both inhibitors displayed a significant 
effect at reducing the cytokine levels of TNF (Figure 41D). Altogether, these results 
validate that the IRE1-XBP1 pathway is associated with the higher expression of 
TNF and IL-6 in M1 macrophages from patients with CF. 
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Figure 41 – IRE1 inhibition reduces TNF and IL-6 secretion in CF M1 
macrophages. 
The IRE1 inhibitors 4μ8c (50 μM) and MKC-3946 (10 μM) were used 30 min before 
M1 macrophages activation. (A) Polarised M1 macrophages from HC volunteers (n=9) 
and patients with CF (n=9) are presented as percentage M1 of total macrophages 
measured by flow cytometry. (B) BiP, XBP1s, ERdj4, TNF, and IL-6 mRNA relative 
expression were quantified in M1 macrophages from HC volunteers (n=6) and patients 
with CF (n=6). (C and D) IL-6 and TNF cytokine levels in M1 macrophages measured 
by ELISA, HC volunteers (n=6) and patients with CF (n=6). All data are presented as 
mean ± SEM. Data in panel B are represented by logarithmic scale base 10. Statistical 
comparisons were performed by paired Student's t-test, *p < 0.05, **p < 0.01, ***p < 
0.001. These data have been published by the author [30]. 
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4.4 Discussion 
 
Inflammation is a natural physiological process elicited by several cells in the 
human body. The main goal of the inflammatory response is to recruit other types of 
cells to the site of inflammation, mostly immune cells, in order to recover the tissue 
homeostasis. We have demonstrated that the proportion of the anti-inflammatory 
macrophages, M2, in patients with CF is lower when compared to HC volunteers. 
While the proportion of M1 macrophages was not affected, the amount of IL-6 and 
TNF was certainly increased in patients with CF. These imbalances in the proportion 
of macrophages and the excessive amounts of inflammatory cytokines produced, help 
to explain the chronic and excessive inflammation seen in patients with CF. This 
abnormal response is not only seen in M1 macrophages with CFTR mutations, but 
also in CF HBECs. While the basal levels of IL-6 mRNA were significantly increased 
in all CF HBECs, stimulation of these cells with LPS, Tn and Tg showed varying 
results, regarding the IB3-1 cell line. Stimulation of the IB3-1 cell line with LPS did not 
induce the upregulation in IL-6. Tn reduced the amount of IL-6 transcription, not only 
in the IB3-1 cell line but also in the WT control cell line. Tg showed a consistent 
increasing effect on all HBECs. The CuFi-1 and CuFi-4 CF cell lines showed 
consistently higher levels of IL-6 when compared to the WT cell line. Furthermore, the 
higher levels of IL-6 were reduced by the addition of the IRE1inhibitor, in both the 
WT and the CuFi-1 cell lines. These findings suggest that the increased activity of 
IRE1led to increased levels of IL-6 which can be reduced by inhibition of IRE1 
While no significant differences were recorded neither in lymphocytes nor in 
neutrophils, this is understandable, as these cells are not notable producers of these 
two cytokines. Monocytes from patients with CF showed increased levels of TNF after 
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LPS stimulation, while the levels of IL-6 were not affected. Culture of these cells with 
either Tn or Tg did not elicit a significant response, regarding these two pro-
inflammatory cytokines. As already mentioned, the polarisation ratios were not 
different in patients with CF, regarding M1 macrophages; however, the excessive 
amounts of TNF and IL-6 were reduced by blocking the RNase domain of IRE1The 
reduction in these two pro-inflammatory cytokines were associated with a reduction in 
XBP1s, with no difference in the polarisation ratios of the M1 macrophages. These 
findings suggest that an overactive IRE1-XBP1 pathway is responsible for the 
excessive amount of TNF and IL-6 produced by M1 macrophage in patients with CF. 
The abnormal levels of pro-inflammatory cytokines may be responsible for the lung 
damage and the decreased respiratory capacity observed in patients with CF. 
Moreover, this may help to explain the pancreatic inflammation seen in patients with 
CF-related diabetes. While certain discrepancies exist in whether the CFTR is 
expressed by immune cells, we observed CFTR expression in both M1 and M2 
macrophages. The degree of CFTR staining was increased after permeabilisation of 
the macrophages. These differences could be due to increased contact of the CFTR 
specific antibody with the transmembrane channel, or due to the expression of the 
CFTR in cellular organelles. In summary, it was demonstrated that the levels of TNF 
and IL-6 were significantly increased, mainly in M1 macrophages from patients with 
CF. Furthermore, the excessive levels of these two pro-inflammatory cytokines were 
driven by an overactive IRE1-XBP1 pathway. 
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Chapter 5 – Metabolism in Cells with CF Mutations 
and the Effects of IRE1 Inhibition 
5.1 Introduction 
 
Metabolism plays a vital role during different cellular processes, and it is crucial 
during cellular differentiation and activation, particularly in immune cells [183]. In fact, 
the UPR has been linked with immunometabolism and dysregulation of the UPR has 
been reported to be in a number of different diseases [30, 140, 210]. Furthermore, the 
IRE1-XBP1 pathway of the UPR has been shown to be involved in the regulation of 
metabolic pathways involving immune cells [140]. Since XBP1s has been shown to be 
significantly upregulated in M1 macrophages from patients with CF, we hypothesised 
that these increased levels of XBP1s might play an essential role in the regulation of 
metabolism in these pro-inflammatory cells. Moreover, based on some preliminary 
data, generated by our group, showing increased levels of extracellular acidification 
rate (ECAR) and oxygen consumption rate (OCR) in monocytes, expansion these 
findings was sought by investigating immunometabolism in monocyte and 
macrophage from patients with CF. Frequently, patients with CF receive a high caloric 
diet to compensate for the lack of nutrients, mostly due to malabsorption in the gut. 
Malabsorption is both a consequence of pancreatic dysfunction and small intestinal 
pathology in CF, which leads to malnutrition and weight loss. It was investigated 
whether monocytes and macrophages showed alterations and abnormalities in 
metabolism, which could be associated with the increased energy demands in patients 
with CFTR mutations.   
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5.2 Methods 
 
5.2.1 Cellular ROS detection in HBECs and M1 macrophages 
For detection of ROS in the HBEC lines, the following steps were followed; 
BEAS-2B and CuFi-1 cells were detached from the flasks, as previously described in 
the main methods section, washed 2 times with DBPS and seeded into 96 well plates, 
with a clear flat bottom and black sides, at a concentration of 2.5X104 cells per well 
and left overnight to allow the attachment of the cells. The next day, cells were washed 
once with the buffer provided and stained using 25 μl of DCFDA, diluted in the buffer 
provided, and left for 45 min in the incubator at 37°C. After the incubation period, cells 
were washed once with the washing buffer and stimulated for 4 h in the incubator. 
Levels of ROS were measured after the stimulation, as described in the main methods 
section. A total of 3 to 4 technical replicates were used per stimulation.   
The same protocol used for M1 macrophages as for the cell lines, with the following 
modifications. M0 macrophages were grown for 6 days, as per the M1 macrophage 
protocol, described above. Before activation, macrophages were detached from the 
wells and seeded into 96 well plates with a clear flat bottom and black sides at a 
concentration of 3.0X104 cells per well and activated with LPS/IFN for 24 h. The next 
day, cells were washed once with the buffer provided and stained using 25 μl of 
DCFDA, diluted in the buffer provided, and left for 45 min in the incubator at 37°C. 
After the incubation period, cells were washed once with the washing buffer and 
stimulated for 4 h in the incubator. The detection of ROS was measured as described 
before after the stimulation. A total of 3 to 4 technical replicates were used per 
stimulation.   
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5.2.2 Mitochondrial ROS (mitoSOX) detection 
Mitochondrial ROS (mROS) were detected using MitoSOX, following the 
manufacturer’s recommendation. Briefly, 13 μl of sterile DMSO was incorporated into 
one vial of MitoSOX (to make 5 mM MitoSOX solution), and dissolved into DPBS 
1/1000 to a final concertation of 5 μM MitoSOX reagent working solution. Then HBECs 
were detached, counted and transferred into FACS tubes at 0.5X106 cells per tube. 
Cells were stimulated with 50ng of LPS for 4 h, then the media was removed, and the 
cells were washed with PBS. 5 μM MitoSOX reagent working solution was added into 
the tubes, 500 l of the mix, and incubate at 37°C for 10 minutes. Then the cells were 
washed 2 times with DPBS supplemented with 2% FBS. Finally, the cells were 
resuspended in BSB and run the cells through the flow cytometer. 
 
5.2.3 Glycolytic and mitochondrial assays 
The glycolytic assays were done using the following protocol, as previously 
published [30].  Negatively isolated monocytes were seeded into a density of 1.0 × 105 
in XF96 cell-culture microplates previously coated with CellTak (Corning), according 
to the manufacturer’s instructions, and wait for 1 h for cellular adherence. Immediately 
after, the levels of ECAR and OCR were measured on an XFe96 Extracellular Flux 
Analyzer (Agilent). For the experiments involving M1 macrophages, cells were grown 
as described in the M1/M2 macrophage polarization section; on day 6, the cells were 
detached, using Accutase (Thermo Fisher Scientific), and seeded at a density of 3.0X 
104 in XF96 cell-culture microplates. The inhibitory effects of 48c 50 μM (Merck) and 
MKC-3946 10 μM (Cayman Chemical) were examined by pre-treating macrophages 
30 min before the addition of LPS and IFN, and then the cells were cultured for a 
further 24 h in complete RMPI medium for full activation. After activation, the 
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supernatants were collected for cytokine detection, the cells were washed twice and 
media changed to Agilent seahorse XF base medium containing 10 mM Glucose (only 
for the Mito Stress Kit), 2 mM L-glutamine, 1 mM sodium pyruvate, and 1 mM HEPES. 
ECAR and OCR measurements were analysed on an XFe96 Extracellular Flux 
Analyzer (Agilent). Once basal ECAR and OCR measurements were obtained, ECAR 
changes in response to glucose (10 mM) were recorded, oligomycin (1 μM), 2-Deoxy-
D-glucose (2-DG, 50 mM), following the instructions outlined in the XF Cell Glycolysis 
Stress Test Kit (Agilent), or stimulated with oligomycin (1 μM), FCCP (1 μM), and 
rotenone/antimycin A (0.5 μM) following the instructions stated in the XF Cell Mito 
Stress Test Kit (Agilent). 
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5.3 Results 
 
5.3.1 Increased ROS and mitochondrial ROS in CF HBECs 
HBECs with CF mutations showed an altered inflammatory profile, with 
activation of the UPR and high levels of XBP1s being observed. The UPR is a complex 
mechanism that can be activated in response to several stimuli [129, 211, 212]. ROS 
are naturally formed during oxygen metabolism, producing superoxide (O2−), which is 
normally the first step in the formation of other types of ROS [213]. When active, the 
UPR has been shown to induce the formation of ROS, and this interplay is associated 
with the production of inflammatory cytokines [152, 214, 215]. This link between UPR 
and ROS formation made us speculate that cells with CFTR mutations have increased 
levels of ROS, with potential implications for the inflammatory response. Under basal 
conditions, the CuFi-1 cell line showed increased levels of ROS when compared to 
the WT HBEC line (Figure 42A). These heightened levels produced by the CF cell 
line were further significantly increased upon stimulation with LPS and Tg (Figure 
42A). Incubation of the CuFi-1 cell line with the natural antioxidant glutathione (GSH), 
led to a significant reduction in the levels of ROS (Figure 42A). Moreover, not only the 
levels of ROS were altered in the CuFi-1 cell line, but also the basal levels of 
mitochondrial ROS (mROS) were significantly increased (Figure 42B). In summary, 
we confirmed that the levels of ROS and mROS were elevated in cells with CFTR 
mutations. Furthermore, these increased levels of ROS and mROS may be associated 
with the high levels of pro-inflammatory cytokines and XBP1s production by these 
cells.   
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Figure 42 – Increased levels of ROS and mROS in CF HBECs 
The levels of ROS and mROS were measured in the two HBECs, BEAS-2B (WT) and 
CuFi-1 (F508/F508). The levels of ROS were measured under basal condition or 
upon stimulation of LPS (100 ng/ml) and Tg (300 nM) for 4 h. When mentioned, the 
antioxidant glutathione (GSH) was included in the culture media at a concentration of 
5mM. gBasal, gLPS and gTg represent conditions where 5 mM glutathione was 
present in the culture media. All data are presented as mean ± SEM. Statistical 
significance was determined by using unpaired or paired Student's t-test. *p < 0.05, 
**p < 0.01, ***p < 0.001. n=4 biological replicates for all cell lines. 
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5.3.2 Increased ROS in CF M1 macrophages 
The increased levels of ROS and mROS in the CF HBECs led us to investigate 
whether macrophages from CF patients showed an increased production of ROS. As 
previously shown, M1 macrophages from CF patients showed significantly higher 
levels of IL-6 and TNF that were associated with the higher expression of XBP1s. The 
amount of ROS that were formed in the M1 macrophages from CF patients was 
significantly higher when compared to HC volunteers (Figure 43); however, upon 
stimulation with LPS, the significantly higher levels of ROS observed in the CF M1 
macrophages were lost (Figure 43). 
 
Figure 43 – Increased levels of ROS in CF M1 macrophages 
The levels of ROS were measured in fully polarised M1 macrophages from HC 
volunteers (n=5) and patients with CF (n=5). The levels of ROS were measured 
under basal condition or upon stimulation of LPS (100 ng/ml). All data are presented 
as mean ± SEM. Statistical significance was determined by using unpaired Student's 
t-test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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5.3.3 Heightened glycolytic rate and mitochondrial flux in CF monocytes 
Next, we investigated metabolism in monocytes and macrophages from HC 
volunteers and patients with CF, by using the Seahorse XFe96 Analyzer. Through the 
utilisation of this instrument, we can assess the glycolytic rates by measuring the 
ECAR, and the mitochondrial flux by measuring OCR. Under basal conditions, 
monocytes from CF patients presented higher levels of ECAR when compared to the 
HC volunteers, with no significant difference in OCR (Figure 44A and B). CF 
monocytes, stimulated with LPS, showed significantly higher levels of both ECAR and 
OCR (Figure 44A and B). These findings suggest that monocytes with CFTR 
mutations utilise oxygen more rapidly only when exposed to a bacterial challenge. The 
process of converting glucose to pyruvate, better known as glycolysis, can be 
measured by the addition of glucose to the medium culture (Figure 45). Furthermore, 
the glycolytic capacity of the cells can also be measured by the addition of oligomycin, 
which effectively stops oxidative phosphorylation (OxPhos) and switches metabolism 
towards glycolysis. Similarly, the glycolytic reserve of the monocytes can be measured 
by the addition of 2-deoxy-glucose (2-DG), a glucose analogue that inhibits glycolysis 
(Figure 45). While the ECAR basal levels were significantly higher in the CF 
monocytes, glycolysis was not shown to be altered (Figure 44C and D); conversely, 
the glycolytic capacity and reserve of the monocytes from CF patients were 
significantly higher (Figure 44C and D). Altogether, monocytes from CF patients have 
an altered glycolytic function with higher ECAR levels and increased glycolytic 
capacity and reserve.  
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Figure 44 – Increased mitochondrial flux and glycolytic rates in CF monocytes. 
ECAR and OCR of monocytes stimulated with glucose (10 mM), oligomycin (1 μM), 
and 2-Deoxy-D-glucose (2-DG, 50 mM). (A–D) Measurement of relative OCR (A) or 
ECAR (B) in monocytes from HC volunteers (n=7) and patients with CF (n=7) under 
basal conditions and stimulated with LPS (10 ng/ml) for 4 h. The Levels of glycolysis, 
glycolytic capacity and reserve were measured (C and D). Glycolysis, glycolytic 
capacity, and reserve were calculated as described in the methods. All data is 
presented as mean ± SEM. Statistical comparisons were performed by unpaired 
Student's t-test, *p < 0.05, **p < 0.01, ***p < 0.001. These data have been published 
by the author [30]. 
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Figure 45 – Glycolytic function 
The measurement of Glycolysis, glycolytic capacity and reserve were measured as 
follow: sequential application of glucose (Glu) oligomycin (Oligo) and 2-deoxy-glucose 
(2-DG) were carried to dissect basal ECAR, glycolysis, glycolytic capacity, and 
glycolytic reserve. 
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5.3.4 Heightened mitochondrial flux and glycolytic rate in CF M1 macrophages 
After finding that monocytes with CFTR mutations had altered ECAR and OCR, 
we sought to investigate the metabolic profile of M1 macrophages, as these cells are 
metabolically more active. CF M1 macrophages showed increased levels of ECAR 
and OCR as compared to the HC M1 macrophages (Figure 46A and B). Differently 
than monocytes, M1 macrophages from CF patients showed these raised ECAR and 
OCR levels before and after polarisation of the cells with LPS/IFN (Figure 46A and 
B). The sequential stimulation of the macrophages with glucose, oligomycin and 2-
DG, revealed an increased glycolytic capacity and reserve in the M1 macrophages 
from patients with CF, as also seen in the CF monocytes (Figure 46C and D). 
Interestingly, glycolysis was not shown to be altered. Following on from these findings, 
we analysed the mRNA expression of some important metabolic enzymes involved in 
glycolysis and mitochondrial function; hexokinase 2 (HK2), pyruvate dehydrogenase 
kinase 4 (PDK4), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB1), 
oestrogen-related receptor alpha 1 (ESRRA), peroxisome proliferator-activated 
receptor alpha (PPARA), and uncoupling protein 3 (UCP3). The expression of PDK4, 
PFKFB1, ESRRA and UCP3 were not shown to be altered in the M1 macrophages 
(Figure 47); however, the mRNA levels of HK2 and PPARA were shown to be 
significantly downregulated in the CF M1 macrophages, compared to the HC (Figure 
47). These findings suggest that the metabolic profile of M1 macrophages with CFTR 
mutations is altered, showing high ECAR and OCR with no change in glycolysis, but 
with a significant increase in the glycolytic capacity and reserve. 
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Figure 46 – Increased mitochondrial flux and glycolytic rates in CF M1 
macrophages. 
ECAR and OCR of M1 macrophages stimulated with glucose (10 mM), oligomycin (1 
μM), and 2-Deoxy-D-glucose (2-DG, 50 mM). (A–D) Measurement of relative OCR (A) 
or ECAR (B) in M1 macrophages from HC volunteers (n=7) and patients with CF (n=7) 
under basal conditions and stimulated with LPS/IFN. The Levels of glycolysis, 
glycolytic capacity and reserve were measured (C, D). Glycolysis, glycolytic capacity, 
and reserve were calculated as described in the methods. All data are presented as 
mean ± SEM. Statistical comparisons were performed by unpaired Student's t-test, *p 
< 0.05, **p < 0.01, ***p < 0.001. These data have been published by the author [30]. 
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Figure 47 – mRNA expression of metabolic enzymes in M1 macrophages.  
The relative mRNA expression of PDK4, PFKB1, HK2, ESRRA, PPARA, and UCP3 
were measured in M1 macrophages from HC volunteers (n=5) and patients with CF 
(n=5). All data are presented as mean ± SEM and mRNA data represented by 
logarithmic scale base 10. Statistical comparisons were performed by unpaired 
independent Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. These data have 
been published by the author [30]. 
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5.3.5 IRE1 inhibition recovers the heightened glycolytic rate and mitochondrial flux 
Glycolysis is the first obligated pathway to convert glucose into pyruvate. 
Followed by this process, pyruvate enters the Krebs cycle to be converted into ATP 
within the electron transport chain. As shown before, both the ECAR and OCR were 
elevated in M1 macrophages from CF patients; therefore, it was sought to evaluate 
mitochondrial flux, including the maximal respiration, reserve respiratory capacity and 
ATP production in M1 macrophages. These parameters can be evaluated by the 
sequential addition of oligomycin, carbonyl cyanide-4-phenylhydrazone (FCCP) and 
rotenone/antimycin A (Figure 48). The ECAR and OCR levels were significantly 
elevated in the M1 macrophages from CF patients (Figure 49A-C). Furthermore, while 
not significantly different, the maximal respiration and reserve respiratory capacity of 
CF M1 macrophages were elevated (Figure 49D). In contrast, the ATP production 
was shown to be significantly higher in the M1 macrophages from CF patients, when 
compared to HC volunteers (Figure 49D). As XBP1s was shown to be significantly 
elevated in the CF M1 macrophages, we next evaluated whether inhibition of IRE1, 
with 48c and MKC-3946, would have an impact in the raised ECAR and OCR levels. 
Inhibition of the IRE1-XBP1 signalling pathway significantly decreased the 
heightened ECAR and OCR levels seen in the M1 macrophages from patients with 
CF (Figure 49A and B). Furthermore, both inhibitors significantly reduced the 
heightened basal respiration, maximal respiration, reserve respiratory capacity and 
ATP production in the CF M1 macrophages to a level which was comparable to the 
HC M1 macrophages (Figure 49D). In summary, inhibition of the IRE1-XBP1 
signalling pathway decreases the hyper-metabolic state seen in M1 macrophages 
from patients with CF. 
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Figure 48– Mitochondrial function 
The measurement of basal respiration, ATP production, proton leak, maximal 
respiration and spare respiratory capacity were measured as follow: sequential 
addition of oligomycin (Oligo), carbonyl cyanide-4-phenylhydrazone (FCCP) and 
rotenone/antimycin A were carried to dissect the parameters previously mentioned. 
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Figure 49 – The IRE1-XBP1 pathway regulates metabolism in CF M1 
macrophages.  
(A-C) ECAR and OCR levels were measured in M1 macrophages from HC volunteers 
(n=9) and patients with CF (n=9). Cells were stimulated with oligomycin (1 μM), FCCP 
(1 μM), and rotenone/antimycin A (0.5 μM). When mentioned, the IRE1 inhibitors 
48c (50 μM) and MKC-3946 (10 μM) were administrated 30 min before M1 
macrophages polarisation. (C and D) Basal respiration, proton leak, maximal 
respiration, reserve capacity, and ATP production. All the values were calculated as 
described in the methods. All data are presented as mean ± SEM. Statistical 
comparisons were performed by paired or unpaired Student's t-test, *p < 0.05, **p < 
0.01, ***p < 0.001. These data have been published by the author [30]. 
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5.3.6 Ivacaftor reduces OCR levels in CF macrophages with class III mutations 
Ivacaftor is regularly used in the clinic to treat patients with CF, with at least one 
copy of the class III mutation, the most common being G551D mutation. Ivacaftor has 
been shown to be effective in reducing sweat chloride levels and increasing the %FEV 
in this cohort of patients [216]. More recently, it has been shown that levels of the pro-
inflammatory cytokines, IL-and IL-18, are increased in patients with CF [209, 217]. 
Furthermore, we have recent evidence to demonstrate that patients with CF, 
F508/F508, treated with Orkambi for an initial time course of 3 months showed a 
significant reduction in the levels of IL-18 but not IL-(In press); whereas, patients 
receiving tezacaftor and ivacaftor treatment showed a significant reduction in the 
levels of both cytokines, IL-and IL-18 (In press). Taking into consideration all these 
data and the fact that M1 macrophages from patients with CF were shown to be hyper-
metabolic and inflammatory, it was then examined whether Ivacaftor reduced the 
increased OCR levels present in macrophages with CFTR mutations. CF M1 
macrophages, with at least one copy of the G551D mutation, were treated with 
Ivacaftor every 48 hours, for the time course of the macrophage differentiation 
process, described in the main methods section. All M1 macrophages treated with 
Ivacaftor showed a reduction in OCR levels at, basal respiration, maximal respiration, 
reserve respiratory capacity and ATP production (Figure 50). The reduction in the 
OCR levels observed in the CF M1 macrophages treated with Ivacaftor was 
comparable to the levels shown by the HC M1 macrophages (Figure 50). We also 
observed that M2 macrophages were metabolically less active when compared to M1 
macrophages. CF M2 macrophages treated with Ivacaftor showed a similar reduction 
in OCR levels, as seen in the M1 macrophages (Figure 50). Overall, these data 
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suggest that Ivacaftor has a significant impact on the metabolic state of CF 
macrophages. 
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Figure 50 – Ivacaftor reduces the increased OCR levels in CF Macrophages.  
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(A-L) ECAR and OCR levels were measured in M1 and M2 macrophages from patients 
with CF (n=4). Cells were stimulated with oligomycin (1 M), FCCP (1 M), and 
rotenone/antimycin A (0.5 M). Macrophages were differentiated, as previously 
mentioned, and treated Ivacaftor (2.5 M) (IVA) when referred. (C, F, I and L) Basal 
respiration, proton leak, maximal respiration, reserve capacity, and ATP production 
were all measured. The green dotted line represents the average basal respiration, 
maximal respiration, reserve capacity, and ATP production in HC M1 macrophages 
(HC=9). All the values were calculated, as described in the methods. All data are 
presented as mean ± SEM. 
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5.3.7 Orkambi selectively reduces OCR levels in CF macrophages (F508/F508) 
While Orkambi is regularly used in the clinic in the US, this pharmaceutical 
compound, at the beginning, was only prescribed under compassionate treatment in 
the UK, due to its cost-inefficient results. Patients with CF, homozygous F508/F508, 
treated with Orkambi, showed an increase in the %FEV1, ranging from 2.6-4.0% [70]. 
Orkambi has been recently fully approved in the UK. It is still not well understood why 
some patients with CF strongly respond when treated with Orkambi, while other 
patients do not respond in a similar manner. We hypothesised that Orkambi, as seen 
with Ivacaftor, may have a similar effect in the regulation of metabolism in 
macrophages from patients with CF, mainly F508/F508. Treatment of CF M1 and 
M2 macrophages with Orkambi showed a degree of variability in OCR levels 
measured, among the patients with CF (Figure 51). Basal respiration and maximal 
respiration were reduced in macrophages from two of the patients with CF, while these 
levels were unaffected in two other patients (Figure 51C, F, I and L). The levels of 
reserve respiratory capacity were reduced in two of the patients with CF while 
unaffected in the other two patients; however, the variability of these levels was below 
the average of the HC macrophages in one of the patients (Figure 51C, F, I and L). 
Interestingly, ATP production was reduced in M1 and M2 macrophages from three of 
the patients with CF, while it was increased in the M1 macrophages from patient CF31 
(Figure 51C, F, I and L). While treatment of CF macrophages with Ivacaftor showed 
a consistent reduction in the mitochondrial parameters evaluated here, culturing CF 
macrophages with Orkambi produced a selective reduction in some of the OCR levels 
represented in this study.       
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Figure 51 – Orkambi partially reduces the increased OCR levels in CF 
macrophages.  
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(A-L) ECAR and OCR levels were measured in M1 and M2 macrophages from patients 
with CF (n=4). Cells were stimulated with oligomycin (1 M), FCCP (1 M), and 
rotenone/antimycin A (0.5 M). Macrophages were differentiated, as previously 
mentioned, and treated with Orkambi (Ivacaftor (2.5 M) and Lumacaftor (2.5 M)) 
(OK) when referred. (C, F, I and L) Basal respiration, proton leak, maximal respiration, 
reserve capacity, and ATP production were all measured. The green dotted line 
represents the average basal respiration, maximal respiration, reserve capacity, and 
ATP production in HC M1 macrophages (HC=9). All the values were calculated as 
described in the methods. All data are presented as mean ± SEM. 
 
5.3.8 Ivacaftor and Symkevi alter the metabolic profile of HBECs 
Symkevi is the successor of Orkambi, replacing Lumacaftor with Tezacaftor. As 
it was seen in the previous sections, Orkambi and Ivacaftor partially reduced the 
increased metabolic rates in M1 and M2 macrophages from CF patients. First, it was 
hypothesised that HBECs with CFTR mutations would show increased metabolic rates 
as shown by the macrophages, and second, that the CFTR modulators would be able 
to decrease these increased levels. HBECs with CFTR mutations showed significantly 
increased levels of OCRs under basal conditions when compared to the WT control 
(Figure 52A). As seen with the macrophages, Symkevi and Ivacaftor reduced the 
OCRs of the CF HBECs, CuFi-1 and CuFi-4, respectively (Figure 52B-E); however, 
when WT HBECs were cultured in the presence of Symkevi, the OCRs were elevated 
(Figure 52C). CF HBECs showed significantly increased levels of basal respiration, 
maximal respiration, ATP production and spare respiratory capacity when compared 
to the WT CFTR cell line (Figure 52F-L). These increased metabolic parameters were 
reduced by the CFTR modulators Symkevi and Ivacaftor (Figure 52F-L); however, 
these parameters were increased by Symkevi in the WT HBEC line (Figure 52F-L). 
No significant differences were detected in ECARs under basal conditions when 
comparing the HBECs (Figure 52G). Then the glycolytic capacity of the cells was 
tested by using a series of injections containing, glucose, oligomycin and 2-DG, as 
 140
shown before. HBECs with CFTR mutations showed no differences in the ECAR levels 
under basal conditions; however, after injection of glucose, CF HBECs showed non-
significant lower ECAR levels when compared to the WT cell line (Figure 53A). 
Interestingly the CFTR modulators did not significantly change the ECAR parameters 
of CF HBEC lines, but Symkevi showed a pronounced effect in increasing the ECAR 
levels in the WT HBEC line (Figure 53C-J). Consistently, the OCR levels of cells with 
CFTR mutations were significantly increased and were decreased by the 
administration of the CFTR modulators Symkevi and Ivacaftor, accordingly (Figure 
53G).     
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Figure 52 – CFTR modulators decrease the high OCR levels in CF HBECs   
(A-L) ECAR and OCR levels were measured in the HBECs NuLi-1 (WT), CuFi-1 
(F508/F508) and CuFi-4 (F508/G551D). Cells were stimulated with oligomycin (1 
M), FCCP (1 M), and rotenone/antimycin A (0.5 M). Cells were cultured under 
basal condition and in the presence of Symkevi, Ivacaftor (2.5 M) and Tezacaftor (2.5 
M), or Ivacaftor alone. Basal respiration, basal ECAR, proton leak, maximal 
respiration, ATP production, spare respiratory capacity, and non-mitochondrial oxygen 
consumption were all measured. These graphs show three independent experiments 
with four technical replicates in each experiment for each cell line and each condition. 
All values were calculated as described in the methods. All data are presented as 
mean ± SEM. (*) Show comparision with the NuLi-1 cell line, (‡) show paired 
comparison between untreated and treated cells. Statistical comparisons were 
performed by unpaired or paired Student's t-test, *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 53 – No impact of CFTR modulators in the ECAR levels of CF HBECs   
(A-J) ECAR and OCR levels were measured in the HBECs NuLi-1 (WT), CuFi-1 
(F508/F508) and CuFi-4 (F508/G551D). Cells were stimulated with glucose, 
oligomycin, and 2-DG. Cells were cultured under basal condition and in the presence 
of Symkevi, Ivacaftor (2.5 M) and Tezacaftor (2.5 M), or Ivacaftor alone. Non-
glycolytic acidification, basal respiration, glycolytic capacity, glycolysis and glycolytic 
reserve were all measured. These graphs show three independent experiments with 
four technical replicates in each experiment for each cell line and each condition. All 
values were calculated as described in the methods. All data are presented as mean 
± SEM. (*) Show comparison with the NuLi-1 cell line, (‡) show paired comparison 
between untreated and treated cells. Statistical comparisons were performed by 
unpaired or paired Student's t-test, *p < 0.05, **p < 0.01, ***p < 0.001. 
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5.4 Discussion 
 
CFTR mutations that are present in innate immune cells from patients with CF 
have shown to be detrimental to cellular function. We have shown a unique signature 
of ER stress genes that are disrupted in innate immune cells from patients with CF. 
These signalling pathways affect the normal innate immune cellular functions, 
exaggerating the inflammatory response with an associated hypermetabolic state. The 
CuFi-1 cell line showed increased levels of ROS and mROS when compared to the 
WT control. We also found elevated ROS levels in M1 macrophages from patients with 
CF, suggesting that these innate immune cells have a disruption in their cellular 
machinery that regulates the function of these molecules. Further investigation into 
the glycolytic pathways employed by these innate immune cells, revealed that 
monocytes and M1 macrophages from patients with CF have a disruption in their 
ECAR and OCR levels. When challenged by bacterial components, monocytes and 
macrophages showed heightened levels of ECAR and OCR levels, as opposed to the 
ratios shown by HC monocytes and M1 macrophages. Intriguingly, when we 
calculated glycolysis in both cells, we did not find any significant changes; 
nevertheless, the glycolytic capacity and reserve in these innate immune cells was 
significantly increased (p<0.05). The glycolytic capacity is defined as the maximum 
rate of conversion of glucose to pyruvate/lactate that a cell can achieve. Converting 
glucose to pyruvate/lactate is carried out by several enzymes within the cytosolic 
space, but this rapid and inefficient method of generating ATP. The glycolytic reserve 
indicates the ability of the cell to acutely respond to an energetic demand, for instance, 
during bacterial challenges. The increased levels in the glycolytic capacity and 
reserve, as found in the CF monocytes and macrophages, indicate that these cells 
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respond in an exaggerated manner to bacterial challenges. These findings suggest 
that the CFTR mutations encountered in these myeloid cells may be associated with 
this exaggerated metabolic response. Considering that circulating monocytes from CF 
patients may be activated and acquire a short innate immune memory or “epigenetic 
memory”, as described by some studies [218-220], this could help to explain the 
increased glycolytic capacity and reserve levels observed; however, we consider that 
on top of this hypothetical epigenetic memory in these cells, the CFTR mutations found 
in innate immune cells may be associated with the increased metabolic rates. Our 
previous results have shown that M1 macrophages from CF patients have increased 
activity in the IRE1-XBP1 signalling pathway, with associated increased levels of 
inflammation and mitochondrial flux. By inhibiting the RNase domain of the IRE1 arm 
of the UPR, we demonstrated that the hyper-metabolic levels, shown by CF M1 
macrophages, are linked to the ER stress found in these cells. Furthermore, while 
decreasing the hyper-metabolic state in these cells, the two IRE1 inhibitors also 
reduced the levels of TNF and IL-6 in the CF M1 macrophages. These findings 
suggest that the CFTR mutations, in these M1 macrophages, lead to increased levels 
of cellular stress with further increased cellular metabolism.  
 Ivacaftor and Orkambi, the most efficient drugs licenced to be administered to 
patients with CF have shown different outcomes in the clinic, with the former drug 
being significantly efficient in treating a subset of patients with CF, and the latter 
showing only a modest efficacy in some of the patients. Orkambi will be eventually 
replaced by its successor, the triple therapy combination Trikafta, which has shown 
improved efficacy in patients F508 homozygous, to the level of patients carrying class 
III mutations taking Ivacaftor alone [75, 77]. Addition of Ivacaftor to the culture media, 
where the macrophages from patients with class III mutations were being 
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differentiated, reduced the increased mitochondrial flux observed in these cells, 
whereas Orkambi only partially reduced these increased metabolic ratios in two of the 
patients who were homozygous for the F508 mutation.      
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Chapter 6 – Discussion 
6.1 The UPR exacerbates inflammation in cystic fibrosis 
 
The UPR is an essential cellular mechanism that eukaryotic cells have evolved to 
detect several pathogenic and stress insults by using the three ER transmembrane 
proteins, ATF6, IRE1, and PERK, which allow cells to recover the equilibrium by 
restoring ER homeostasis. These complex mechanistic pathways have been 
frequently reported to regulate the protein load in neurological disorders [221-223]. 
For instance, in Alzheimer’s and Parkinson’s disease, the protein aggregation within 
the neurons is known to cause ER stress and activate the UPR [224, 225]. Thus, it 
has been hypothesised that UPR activation in these two neurological conditions leads 
to the progression of these disorders, causing neuronal damage with eventual tissue 
destruction [224]. It would be interesting to investigate whether this UPR activation is 
associated with the production of pro-inflammatory cytokines in the brain and whether 
this process can be inhibited by using specific drug compounds. In fact, one hallmark 
of neuroinflammation in patients with Alzheimer’s and Parkinson’s disease, is the 
presence of TNF, IL-1 and IL-6 in the brain, cerebrospinal fluid and serum of these 
patients [226, 227]. The presence of these cytokines could, potentially, be associated 
with the UPR activation seen in these patients.  
In the case of CF, the chronic activation of the IRE1-XBP1 signalling pathway 
may be fundamental in disease progression, in association with the increased 
neutrophilic infiltration normally seen in the lungs of patients with CF. TNF, IL-1and 
IL-6 are potent pro-inflammatory cytokines that regulate the inflammatory response by 
activating monocytes and macrophages. Moreover, TNF and IL-1 enhance the 
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production of IL-8, which induces lung neutrophilic infiltration [228].  A recent study 
demonstrated that the levels of IL-1in the BAL and sputum of patients with CF was 
directly correlated with the %FEV1 [217]. It would be interesting to explore whether 
this chronic UPR activation is linked to the production of IL-1 in CF. It was 
demonstrated that the raised levels of XBP1s are associated with the 
hyperinflammatory response seen in patients with CF. It is worth mentioning, that 
chronic activation of the IRE1-XBP1 signalling pathway was only seen in the M1, but 
not M2 macrophages, suggesting that this process only affects pro-inflammatory 
macrophages. Moreover, the abnormal hyper-inflammatory state of the macrophages 
was observed after activation with LPS and IFN, suggesting that the UPR may act as 
an enhancer of the inflammatory response when activated. The ionic imbalance 
produced by the CFTR abnormalities, alongside the accumulation of the misfolded 
proteins, associated with F508 homozygosity, could induce a perpetual chronic low-
grade inflammation in CF macrophages, directing these phagocytic cells towards a 
hyper-inflammatory phenotype, which is mainly driven by XBP1s. This chronic low-
grade inflammation can be also exacerbated by other PAMPs and DAMPs, such as 
TNF, IL-6, LPS and ROS, as shown in other disorders, such as RA and TRAPS 
(Figure 54) [133, 152]. These mechanisms are potentially crucial for the progression 
of CF, as macrophages are primarily involved in the regulation of the inflammatory 
response.   
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Figure 54 – The IRE1a-XBP1 signalling pathway of the UPR in CF. 
In CF macrophages activation of the IRE1-XBP1 signalling pathway induces the 
XBP1s, which in turn activates the transcription of several genes involved in 
inflammation, protein folding, autophagy and metabolism. CFTR malfunctioning and 
accumulation of misfolded protein induces a low-grade chronic ER stress, leading to 
a hyperinflammatory and –metabolic phenotype. The activation of TLR4, through 
bacterial competes, leads to a further increase in the levels of XBP1s exacerbating 
the inflammatory response. 
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6.2 The UPR and the regulation of macrophage metabolism. 
 
Immunometabolism has proven to be an essential mechanism to consider during 
macrophage differentiation and activation, and a better understanding of the different 
metabolic pathways encountered in these cells is therefore encouraged. Recent 
discoveries have shown that the UPR is an important regulator of cellular metabolism 
[229, 230]. While the UPR positively regulates metabolic pathways in several 
eukaryotic cells, this process also regulates glucose, lipid and mitochondrial 
metabolism in different immune cells [140, 210, 231, 232]. In this study, it was 
demonstrated that monocytes and M1 macrophages from CF patients show increased 
metabolic rates. The increased glycolytic rates and mitochondrial flux levels observed 
in the CF M1 macrophages were associated with increased levels of XBP1s. It was 
confirmed that inhibition of the RNase domain of the IRE1 arm of the UPR leads to 
a reduction in the glycolytic rate and mitochondrial flux in CF M1 macrophages, which 
was comparable to the levels of the HC macrophages. Furthermore, while reducing 
the increased metabolic levels in CF M1 macrophages, inhibition of IRE1 also lead 
to the reduction of TNF and IL-6 pro-inflammatory cytokines. These findings suggest 
that CFTR mutations in human macrophages lead to activation of the IRE1-XBP1 
signalling pathway, which in turns regulates the metabolic profile of these cells. As the 
activity of IRE1 remains increased in these CF M1 macrophages, the rates of some 
metabolic parameters remained also increased, such as the glycolytic capacity and 
reserve, basal cellular respiration and ATP production. These findings support the idea 
that macrophage metabolic regulation, through the UPR, might be a possible 
therapeutic option for patients with CF. Modulation of the metabolic pathways in 
human cells could be an alternative option to treat inflammatory diseases. In fact, 
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recent discoveries have identified the metabolite itaconate as a potent anti-
inflammatory molecule in macrophages, acting through Nrf2, which is capable of 
reducing the inflammation in vivo [199]. This study demonstrated that a derivate of this 
metabolite, 4-octyl itaconate (OI), protected mice against LPS induced lethality and 
reduced the levels of TNF and IL-1secretion [199]. While OI can reduce the 
inflammatory response via Nrf2, IRE1 inhibitors may be used for the same proposes 
when inflammation and metabolic profiles are raised in certain diseases. Although 
these compounds can serve as potent anti-inflammatory drugs, it is essential to 
consider their side effects when administered in vivo, as Nrf2 and IRE1 are critical 
mechanistic pathways that regulate cellular homeostasis. A summary of various 
dysregulated pathways in M1 macrophages is shown in Figure 55.  
Recent studies have shown that the UPR can influence macrophage polarisation 
[210, 233]. In one study, conditional ablation of IRE1 in mouse myeloid cells 
increased the proportion of M2 macrophage polarisation [210]; however, in this study, 
it was not observed any change in macrophage polarisation when the two IRE1 
inhibitors were administered before macrophage polarisation. These discrepancies 
may be due to the differences in species, or due to the short exposure of the two drugs 
in macrophages. It would be interesting to investigate further whether the UPR 
regulates human macrophage polarisation in health and disease. 
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Figure 55 – Altered signalling pathways in CF macrophages 
Macrophages with CFTR mutations show alterations in multiple cellular pathways. The 
mutated CFTR causes ionic imbalance, with accumulation of misfolded protein in the 
case of the DF508 mutations and primes these myeloid cells towards an altered 
immune response or chronically activating other signalling pathways. CFTR 
malfunction primes the overactivation of ENaC, leading to increased Na+ influx, which 
is then compensated by K+ efflux. The increased K+ efflux, combined with increased 
ROS and ATP production, activates the NLRP3 inflammasome with further increased 
IL-1 and IL-18 secretion. CF macrophages have raised levels of TLR4 expression, 
and the resultant overactivation of NF-kB leads to increased TNF and IL-6 production. 
Induction TNF and IL-8 may also occur through NETs by an unknown mechanism. 
Similarly, chronic TLR4 activation, possibly due to the persistent bacterial colonisation 
in the lungs, leads to overactivation of IRE1a, thereby triggering XBP1s. This 
production of XBP1s induces transcriptional activation of several UPR responsive 
genes involving metabolism, inflammation and protein folding. XBP1s overexpression 
induces a low-grade chronic induction of IL-6 and TNF, which exacerbates the 
inflammatory response when combined with other signalling pathways. XBP1s also 
regulate metabolic pathways and, in CF macrophages, the increased metabolic state 
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can be reduced by IRE1 inhibition. Macrophages with CFTR mutations also show 
increased glycolytic flux and mitochondrial respiration. It is known that in M1 
macrophages the Krebs cycle favours the accumulation of succinate and citrate. 
Succinate accumulation leads to stabilisation of HIF-1, which can induce IL-1 
production and activation of glycolytic genes. It may be possible that in CF 
macrophages, this axis is favouring a proinflammatory response and increased 
glycolytic function. Alternatively, citrate is converted into aconitate, facilitating the 
synthesis of itaconate, which is a potent anti-inflammatory metabolite; however, the 
role of itaconate in CF is unknown. CF macrophages also display deficient bacterial 
killing with intracellular accumulation of phagocytic vesicles. Altogether, these 
mechanisms influence the altered innate response elicited by macrophages. 
Abbreviations: LDHA (lactate dehydrogenase A); GLUT (glucose transporter); SDH 
(Succinate dehydrogenase); PDH (Pyruvate dehydrogenase); ER (endoplasmic 
reticulum); HIF-1a (Hypoxia Inducible Factor 1 Subunit Alpha); NRF2 (Nuclear factor 
erythroid-2-related factor 2); ATF3 (Activating transcription factor 3); ROS (reactive 
oxygen species). This figure is part of a manuscript in press by the author Lara-Reyna 
et al. CMLS 2020. 
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6.3 Abnormal metabolic and inflammatory profiles in CF HBECs 
 
In this study, it was reported that cells with CFTR mutations showed increased 
metabolic and inflammatory profiles. It is interesting to mention that CF HBECs 
showed increased levels of TNF and IL-6, which were associated with the increased 
OCR levels, as similarly shown by the M1 macrophages; however, HBECs did not 
show any significant differences in the ECAR levels. In the case of the M1 
macrophages, it is known that higher glycolytic activity is associated with an 
inflammatory profile, while the opposite is the case in terms of M2 macrophages. 
Intriguingly, CF HBECs only showed increased OCR ratios with high basal respiration 
and ATP production, suggesting that the mitochondria are affected in cells with CFTR 
mutations, but glycolysis seems not to be affected. High OCR levels indicate a more 
rapid utilization of oxygen by typically by the ETC, which will is utilised as the final 
electron acceptor in the production of ATP. Perhaps the higher metabolic profile of CF 
HBECs is linked to the hyperactive mitochondria which eventually leads to the 
production of ROS and activation of the UPR. Certainly, cells with CFTR mutations 
have an abnormal metabolic activity that can be associated with a unique UPR 
activation and higher production of inflammatory cytokines.  
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6.4 CF as an autoinflammatory condition  
 
As opposed to autoimmunity, autoinflammation involves the aberrant activation of 
the innate immune system causing the abnormal production of inflammatory 
cytokines, whereby the local environmental factors may predispose the cells to an 
inflammatory phenotype [234]. This concept has been previously shown to be one of 
the principal causes that induce inflammation in several immune related-disorders 
including, familial Mediterranean fever (FMF), TRAPS, hyperimmunoglobulinemia D 
syndrome (HIDS) and cryopyrin-associated periodic syndrome (CAPS) [23, 234, 235]. 
CF has been described as an autoinflammatory condition before, due to the CFTR 
dysfunction, which results in a series of pathophysiological complications mainly 
associated with the innate immune system [23]. Recent studies have shown that the 
levels of the pro-inflammatory cytokines IL-1 and IL-18 are increased in patients with 
CF [209, 217]. These results support the idea that CF should be considered as an 
autoinflammatory condition due to substantial similarities with other conditions related 
to the innate immune system. For instance, we have shown that innate immune cells 
with CFTR mutations, mainly macrophages, have increased activity in the IRE1-
XBP1 signalling pathway, which leads to an exaggerated secretion of TNF and IL-6. 
Furthermore, the levels of ROS and mROS were shown to be increased in CF HBECs 
and macrophages. Altogether, these findings support the idea that CF is mainly an 
autoinflammatory condition as the adaptive immune system is not required for this 
exaggerated inflammatory response. It is essential to mention that while T and B cells 
are crucial players in any bacterial and viral infection, these cells have not been 
reported to be primarily affected by CFTR mutations to date. The constant interaction 
between innate and adaptive immune cells is crucial to maintain the equilibrium in 
 157
different tissues and to protect the host against different types of infections. It would 
be interesting to investigate the interaction between the innate and adaptive immune 
system in CF, and whether any abnormalities exist during these processes.  
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6.5 Conclusion  
 
We have shown that innate immune cells containing CFTR mutations have 
dysregulated intracellular mechanism, including increased ER stress, metabolic and 
inflammatory levels. Monocytes and macrophages are essential cells capable of 
controlling the inflammatory response, and, in this study, it was demonstrated that 
mutations in the CFTR gene compromise these functions. To the best of our 
knowledge, CF is an autoinflammatory condition and treatments that regulate the 
inflammatory response, such as IL-6, TNF, IL-1 and IL-18 blockers, should be 
considered. Furthermore, only innate immune cells from patients with CF showed a 
chronic low-grade UPR activation, mainly in the IRE1-XBP1 signalling pathway. The 
results in this study support previous findings that have demonstrated that the IRE1-
XBP1 signalling pathway regulates the metabolic activity of other immune cells. It was 
observed that the increased UPR signalling pathway controls the metabolic rate of CF 
M1 macrophages. Furthermore, these metabolic abnormalities were found in several 
CF innate immune cells, including CF HBECs, monocytes and M1 macrophages. 
These metabolic dysregulations affected the ECAR and OCR levels of all innate 
immune cells previously mentioned.  Remarkably, the two IRE1inhibitors, 48c and 
MKC-3946, reversed the increased inflammatory and metabolic levels in M1 
macrophages.  
Altogether, chronic activation of the IRE1-XBP1 signalling pathway in M1 
macrophages from patients with CF, results in increased ECAR and OCR levels. 
Moreover, these heightened metabolic levels were associated with an exaggerated 
inflammatory repose. CF M1 macrophages undergo metabolic reprogramming, via the 
IRE1-XBP1 signalling pathway, which leads to higher mitochondrial and glycolytic 
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activity, with increased levels of TNF and IL-6. These findings may help to explain the 
clinical complications of patients with CF, who suffer from chronic infections and 
unresolved lung inflammation. Dysregulation of the CFTR conductance alongside with 
the CFTR protein abnormalities lead to increased levels of ER stress in CF 
macrophages. These ER stress levels prime CF macrophages to a hyper-
inflammatory and metabolic response, which is mainly driven by XBP1s and 
exacerbated by the activation of TLR4, and possibly other DAMPs and PAMPs (Figure 
54). The IRE1 axis of the UPR has been shown to be an important player in the 
regulation of inflammation and metabolism, suggesting that modulation of ER stress 
might be an option to recover the cellular equilibrium of immune cells. 
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6.6 Study limitations 
 
While it was demonstrated that the mitochondrial flux, glycolytic rate, ER stress 
and inflammatory profile of cells with CFTR mutations are increased, the following 
limitations are acknowledged in this study. While it was observed an upregulation of 
several ER stress markers in the IB3-1, CuFi-1 and CuFi-4, when compared to 
BEAS2-B, these are immortalised cell lines from different individuals. Also, the IB3-1 
and BEAS2-B cell lines were cultured in LHC basal medium while the CuFi-1 and 
CuFi-4 were cultured in LHC-9 medium; nevertheless, we were able to corroborate 
the high metabolic levels in the CuFi-1 and CuFi-4 cells when compared with the NuLi-
1 cell line, which was cultured in the same conditions CuFi-1 and CuFi-4 cells lines. 
Furthermore, the fact that similar findings were observed in primary human cells from 
patients with CF supports the hypothesis stated in this study. While it was observed a 
constant and significant upregulation of TNF and IL-6 in monocytes and macrophages 
from patients with CF, these differences might be due to a short epigenetic memory of 
these innate immune cells. Moreover, the fact that macrophages were grown in vitro 
for the duration of the experiments and the fact that these cells were grown adding 
MCS-F and GM-CSF limits this study; however, this is a well-established method for 
culturing macrophages, which has demonstrated to be reliable and comparable to in 
vivo macrophages. 
 
 
 
 161
6.7 Future Directions 
 
Following from the limitations mentioned before, it would be interesting to 
investigate further the differences observed in this study in other models of airway 
inflammation, possibly using isogenic corrected induced pluripotent stem cells (iPSc) 
to create HBECs and macrophages. Furthermore, to fully understand all the 
transcriptomic differences in macrophages with CFTR mutations, it would be ideal to 
perform RNAseq in these myeloid cells. For instance, the transcriptomic differences 
between CF and HC monocytes, M0, M1 and M2 macrophages could be explored. 
While there are specific cellular abnormalities associated with inflammatory and 
metabolic pathways in innate immune cells from patients with CF, the underlying 
mechanisms are still not fully deciphered, and more research is encouraged. 
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